Title:  A 12-Week, Phase 2 Randomized, Placebo -Controlled, Double-Blind Study to Assess the 
Efficacy, Safety, and Tolerability of Gemcabene in Subjects with Hypercholesterolemia Not 
Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Thera py (ROYAL -1) 
 
NCT ID:  [STUDY_ID_REMOVED]  
 
Approval Date:  10-Ju l-2017 
*HPFDEHQH *HPSKLUH7KHUDSHXWLFV,QF
6WDWLVWLFDO$QDO\VLV3ODQ*(0 -XO\
 

&RQILGHQWLDO 3DJHRI6WDWLVWLFDO$QDO\VLV3ODQ*(0 
6WXG\7LWOH $:HHN3KDVH5DQGRPL]HG3ODFHER
&RQWUROOHG'RXEOH %OLQG6WXG\WR$VVHVVWKH
(IILFDF\6DIHW\DQG7ROHUDELOLW\RI*HPFDEHQH LQ
6XEMHFWVZLWK+\SHUFKROHVWHUROHPLD1RW$GHTXDWHO\
&RQWUROOHG RQ+LJK,QWHQVLW\RU0RGHUDWH ,QWHQVLW\
6WDEOH6WDWLQ7KHUDS\52<$/
6WXG\1XPEHU *(0
6WXG\3KDVH 3KDVH
6SRQVRU *HPSKLUH7KHUDSHXWLFV,QF
1/DXUHO3DUN'ULYH6XLWH 
/LYRQLD0LFKLJDQ 
8QLWHG6WDWHV 
7HOHSKRQH 
)DFVLPLOH
9HUVLRQ $PHQGPHQW
'DWH -XO
5HYLVLRQ+LVWRU\
9HUVLRQ 'DWH 5HYLVLRQ$XWKRU &RPPHQWV
$PHQGPHQW -XO\  6HH'RFXPHQW+LVWRU\IRUVX[COMPANY_003]U\RI
FKDQJHV
   


Confidentiality Statement 
7KLVGRFXPHQWFRQWDLQVFRQILGHQWLDODQGSURSULHWDU\LQIRUPDWLRQ DQGLVQRWWR
EHGLVWULEXWHGWRDQ\WKLUGSDUW\
PI
[INVESTIGATOR_562392]. 
Statistical Analysis Plan: GEM-[ADDRESS_739102] Disposition ................................................................................................20  
10.2  Demographics and Baseline Characteristics ..................... .....................................20  
10.3  Treatment Compliance and Exposure ............................. .......................................21  
10.3.1  Treatment Compliance .......................................... .......................................21  
10.3.2  Treatment Exposure .....................................................................................22  
11 EFFICACY PARAMETERS ........................................... ................................................23  
11.1  Primary Analysis .............................................. ......................................................23  

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 July 2017 
  
 
Confidential Page 3 of 43 11.2  Secondary Analysis ............................................ ....................................................23  
11.3  Exploratory Analysis .............................................................................................25  
11.4  Manuscript Analysis ........................................... ...................................................26  
12 SAFETY AND TOLERABILITY ....................................... ............................................27  
12.1  Adverse Events ................................................ ......................................................27  
12.2  Clinical Laboratory Assessments ...........................................................................28  
12.3  ECGs ......................................................................................................................30  
12.4  Vital Signs and Weight ..........................................................................................31  
12.5  Physical Examinations ...........................................................................................31  
13 OTHER RELEVANT DATA ANALYSES/SUMMARIES ...........................................[ADDRESS_739103] OF APPENDICES 
Appendix 1.  Schedule of Assessmen ts and Procedures ........................ ..................................34  
Appendix 2.  Prior and Concomitant Medications and Smoking Status Date Imput ation .......37  
Appendix 3.  ATC Categories and Descriptions of Hypertensive Treatments .... ....................38  
Appendix 4.  Sex-specific Framingham Risk Score algorithms ................. .............................42  
Appendix 5.  Manuscript Analyses ........................................... ...............................................43  
 
 

*HPFDEHQH *HPSKLUH7KHUDSHXWLFV,QF
6WDWLVWLFDO$QDO\VLV3ODQ*(0 -XO\
 

&RQILGHQWLDO 3DJHRI2SIGNATURE [CONTACT_1783] 
6WXG\7LWOH $:HHN3KDVH5DQGRPL]HG3ODFHER&RQWUROOHG
'RXEOH%OLQG6WXG\WR$VVHVVWKH(IILFDF\6DIHW\DQG
7ROHUDELOLW\RI*HPFDEHQHLQ6XEMHFWVZLWK+\SHUFKROHVWHUROHPLD 
1RW$GHTXDWHO\&RQWUROOHGRQ+LJK,QWHQVLW\RU
0RGHUDWH,QWHQVLW\6WDEOH6WDWLQ7KHUDS\52<$/
6WXG\1XPEHU *(0

3UHSDUHG
E\

5HYLHZHG
E\


$SSURYHG
E\


*HPSKLUH7KHUDSHXWLFV,QF 
$SSURYHG
E\

*HPSKLUH7KHUDSHXWLFV,QF 


PI
[INVESTIGATOR_562393]. 
Statistical Analysis Plan: GEM-301 10 July 2017 
  
 
Confidential Page 5 of 43 Document History â€“ Major changes compared to prev ious versions of the analysis plan 
Version Date Changes 
Final 1.0 17-Apr-17 N/A 
Amendment 1.0 10-Jul-17 Added that potentially clinically significant laboratory 
values,  single occurrences, will also be summarized by 
[CONTACT_275097] -intensity stratum. 
Added information on imputing drug interruptions with 
partial start/stop dates to be [ADDRESS_739104] hsCRP  and TG being analyzed using 
ranked ANCOVA.  

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-[ADDRESS_739105] aspartate aminotransferase  
ATC anatomical therapeutic chemical  
BMI body mass index  
BUN blood urea nitrogen  
CFBL change from baseline  
CI confidence interval  
CRF case report form  
CVD cardiovascular disease  
DBP diastolic blood pressure  
DPP dipeptidyl peptidase 
ECG electrocardiogram 
eCRF electronic case report form 
ET early termination  
FAS Full Analysis Set  
FPG fasting plasma glucose  
GFR glomerular filtration rate 
GGT gamma-glutamyl transferase  
HbA1c hemoglobin A1c  
HBV hepatitis B virus 
HCV hepatitis C virus 
HDL-C high-density lipoprotein cholesterol  
HIV human immunodeficiency virus 
HoFH  homozygous familial hypercholesterolemia 

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-[ADDRESS_739106]  
Lp(a) Lipoprotein(a) 
LSM least-squares mean  
MAO monoamine oxidase 
MedDRA Medical Dictionary for Regulatory Activities  
NCEP ATP-III National Cholesterol Education P rogram Adult Treatment Panel II I  
NGAL neutrophil gelatinase-associated lipocalin  
OR odds ratio  
PCS potentially clinically significant  
PCSK9 proprotein convertase subtilisin/kexin type 9  
PPS Per-Protocol Set  
PT preferred term  
QD once daily  
QTcB QT interval corrected for heart rate with Bazettâ€™s formula 
QTcF QT interval corrected for heart rate with Fridericiaâ€™s formula  
SAA serum amyloid A  
SAE serious adverse event  
SAS Safety Analysis Set  
SBP systolic blood pressure  
SD standard deviation  
SE standard error  
SOC system organ class  
TC total cholesterol  
TEAE treatment-emergent adverse event  
TG triglyceride  
TSH thyroid-stimulating hormone 
ULN upper limit of normal 

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 July 2017 
  
 
Confidential Page 8 of 43 VLDL-C very low-density lipoprotein cholesterol  
WHO World Health Organization  

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 July 2017 
  
 
Confidential Page 9 of 43 4 INTRODUCTION 
The purpose of this statistical analysis plan is to describe th e framework for the reporting, 
summarization, and statistical analysis methodology of the safe ty and efficacy parameters 
measured throughout the study. It is based on Protocol GEM-301 (Amendment 3) dated 
[ADDRESS_739107] 2016. 

*HPFDEHQH *HPSKLUH7KHUDSHXWLFV,QF
6WDWLVWLFDO$QDO\VLV3ODQ*(0 -XO\
 

&RQILGHQWLDO 3DJHRI5TRIAL OBJECTIVES 
3ULPDU\2EMHFWLYHV
7KHSULPDU\REMHFWLYHRIWKLVVWXG\LVWRDVVHVVWKHORZGHQVLW \OLSRSURWHLQFKROHVWHURO/'/&
ORZHULQJRIJHPFDEHQHPJRQFHGDLO\4'FRPSDUHGWRSODFHE RLQVXEMHFWVZLWK
K\SHUFKROHVWHUROHPLDQRWDGHTXDWHO\FRQWUROOHGRQKLJKLQWHQVLW \RUPRGHUDWHLQWHQVLW\VWDEOH
VWDWLQWKHUDS\WUHDWHGIRUZHHNV
6HFRQGDU\2EMHFWLYHV
7KHVHFRQGDU\REMHFWLYHVRIWKLVVWXG\DUHWKHIROORZLQJ
Â‡WRDVVHVVWKH/'/&ORZHULQJRIJHPFDEHQHPJLQVXEMHFW VRQKLJKLQWHQVLW\VWDEOH
VWDWLQWKHUDS\DQGVXEMHFWVRQPRGHUDWHLQWHQVLW\VWDEOHV WDWLQWKHUDS\WUHDWHGIRU
ZHHNV
Â‡WRDVVHVVWKHVDIHW\DQGWROHUDELOLW\RIJHPFDEHQHPJLQDOOVXEMHFWVFRPELQHGDQG
VHSDUDWHO\LQVXEMHFWVRQKLJKLQWHQVLW\VWDEOHVWDWLQWKHU DS\DQGVXEMHFWVRQ
PRGHUDWHLQWHQVLW\VWDEOHVWDWLQWKHUDS\WUHDWHGIRUZHHNV DQG
Â‡WRDVVHVVWKHHIIHFWRIJHPFDEHQHRQRWKHUOLSLGDQGDSROLSRSUR WHLQ$SRSDUDPHWHUV
KLJKVHQVLWLYLW\&UHDFWLYHSURWHLQKV&53VHUXPDP\ORLG$6 $$DGLSRQHFWLQ
ILEULQRJHQDQGFDUGLRYDVFXODUULVNRYHUZHHNVRIWUHDWPHQW 
([SORUDWRU\2EMHFWLYHV
7KHH[SORUDWRU\REMHFWLYHVRIWKLVVWXG\DUHWKHIROORZLQJ
 

 
 C
I
Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-[ADDRESS_739108] of a 
Pre-Screening Visit (only for subjects requiring a wash-out per iod), a Screening Visit, a 
Treatment Period, and a Follow-up Visit. 
Table 1. Overview of Study Periods 
 Wash-out Period (for 
subjects requiring wash-out) Screening Visit Treatment Period 
Study Days Day -70 to -15, inclusive Day -14 to -1, inclusive Day 1 to 85, inclusive 
Approximately 104 subjects will participate in the study at up to 20 sites in the [LOCATION_002]. 
Subjects are required to be on e ither a high-intensity stable s tatin regimen (atorvastatin at 40 or 
80 mg QD, or rosuvastatin at 20 or 40 mg QD) or a moderate-inte nsity stable statin regimen 
(atorvastatin at 10 or 20 mg QD, rosuvastatin at 5 or 10 mg QD,  or simvastatin at 20 or 
40 mg QD) with or without ezetimibe  [ADDRESS_739109] a fasting LDL-C value â‰¥ 100 mg/dL (2.59 mmol/L) and a TG 
value < 500 mg/dL (5.65 mmol/L) at the Screening Visit, while o n a stable, low-fat, low-
cholesterol diet.  
A wash-out period will be require d for eligible subjects taking  any lipid-regulating therapi[INVESTIGATOR_562394] 10, 20, 40, or 80 mg QD,  rosuvastatin at 5, 10, 20, or 
40 mg QD, simvastatin at 20 or 40 mg QD, and/or ezetimibe at [ADDRESS_739110]â€™s 
current lipid-regulating therapy. Specifically, PCSK9 inhibitors require an 8-week wash-out period, fibrates require a 6-week wash-out period, and niacins along with other lipid-regulating 
therapi[INVESTIGATOR_562395] a 4-week was h-out period. For eligible subjects 
that do not require a wash-out period, the Screening Visit will be their first study visit. 
Subjects will be randomized on D ay 1 in a 1:1 ratio (gemcabene 600 mg to placebo). 
Randomization will be stratified by [CONTACT_562400]-intensity r egimen (moderate or high) and 
diabetes status (yes or no), both of which are recorded on the Medical History form at the 
subjectâ€™s first visit (Pre-Screening or Screening Visit) and updated, when appr opriate, at the 
Screening Visit. Subjects defined as diabetic are those receivi ng concomitant anti-diabetic 
medication at screening. Randomization within a baseline statin -intensity stratum will be capped 
at [ADDRESS_739111]-randomization clinic visi ts will occur at Weeks 2, 4, 8 an d 12. The Follow-up Visit will 
occur 4 weeks (Â± 3 days) after the last dose of the study drug.   

*HPFDEHQH *HPSKLUH7KHUDSHXWLFV,QF
6WDWLVWLFDO$QDO\VLV3ODQ*(0 -XO\
 

&RQILGHQWLDO 3DJHRI6WXG\PHGLFDWLRQZLOOEHDGPLQLVWHUHGRUDOO\4'WKURXJKRXWWKH 7UHDWPHQW3HULRGRIWKHVWXG\
6XEMHFWVUDQGRPL]HGWRUHFHLYHJHPFDEHQHPJZLOOWDNHJHPFD EHQHPJ4'ZKHUHDV
VXEMHFWVUDQGRPL]HGWRUHFHLYHWKHSODFHERZLOOWDNHSODFHER4' 7KHILUVWGRVHRIWKHVWXG\
GUXJZLOOEHDGPLQLVWHUHGDWWKHVLWHRQ'D\2QDOORWKHUGD \VGXULQJWKH7UHDWPHQW3HULRGWKH
VXEMHFWZLOOVHOIGRVH
(IILFDF\0HDVXUHV
7KHSULPDU\HIILFDF\PHDVXUHLVWKHSHUFHQWFKDQJHIURPEDVHOLQ H&)%/WR:HHNLQIDVWLQJ
/'/&KHUHDIWHUUHIHUUHGWRDVÂ³ /'/&Â´
7KHVHFRQGDU\HIILFDF\PHDVXUHVDUH
Â‡SHUFHQW&)%/WR:HHNLQ/'/&ZLWKLQHDFKVWDWLQLQWHQVLW\V WUDWXPPRGHUDWHKLJK
Â‡&)%/DQGSHUFHQW&)%/WR:HHNVDQGLQ/'/&
Â‡&)%/DQGSHUFHQW&)%/WRWKHDYHUDJHRI:HHNVDQGLQ/'/& 
Â‡&)%/DQGSHUFHQW&)%/WR:HHNVDQGLQQRQKLJKGHQV LW\OLSRSURWHLQFKROHVWHURO
QRQ+'/&WRWDOFKROHVWHURO7&7*+'/&DQGYHU\ORZGH QVLW\OLSRSURWHLQ
FKROHVWHURO9/'/&
Â‡SHUFHQWRIVXEMHFWVDFKLHYLQJD/'/&UHGXFWLRQIURPEDVHOLQH RIÂ•Â•DQGÂ• 
DW:HHNVDQG
Â‡SHUFHQWRIVXEMHFWVDFKLHYLQJD/'/&YDOXHPJG/P PRO/DW:HHNVDQG

Â‡&)%/DQGSHUFHQW&)%/WR:HHNVDQGLQ$SR%$SR$,$S R$,,$SR$9
$SR&,,$SR&,,,$SR(DQGOLSRSURWHLQD/S>D@
Â‡&)%/DQGSHUFHQW&)%/WR:HHNLQKV&536$$DGLSRQHFWLQDQ GILEULQRJHQDQG
Â‡&)%/WR:HHNLQ)UDPLQJKDP5LVN6FRUHLH\HDUULVNRIG HYHORSLQJFDUGLRYDVFXODU
GLVHDVH>&9'@
7KHH[SORUDWRU\HIILFDF\PHDVXUHVDUH
 
 

 

 

 

C
I
*HPFDEHQH *HPSKLUH7KHUDSHXWLFV,QF
6WDWLVWLFDO$QDO\VLV3ODQ*(0 -XO\
 

&RQILGHQWLDO 3DJHRIÂ‡ 


'HYHORSHGXVLQJ)UDPLQJKDP+HDUW6WXG\GDWDWKH)UDPLQJKDP5LVN6FRUHLVDQHVWLPDWHRI
DVXEMHFWÂ¶V \HDUULVNRIGHYHORSLQJ&9'ZKLFKLVFRPSXWHGXVLQJVH[VSHFLILFDOJRULWKPVWKDW
FRQWDLQWKHIROORZLQJULVNIDFWRUVDJHV\VWROLFEORRGSUHVVXU H6%3VPRNLQJVWDWXV7&+'/
&WUHDWPHQWIRUK\SHUWHQVLRQDQGGLDEHWHVVWDWXV6PRNLQJVWDWXVUHIHUVWRFLJDUHWWHVPRNLQJ
VWDWXVDQGZLOOEHFROOHFWHGRQFHIRUHDFKVXEMHFWGXULQJWKHV WXG\DQGUHFRUGHGRQWKH0HGLFDO
+LVWRU\&5)6SHFLILFDOO\DVPRNHULVGHILQHGDVDVXEMHFWZKHUHVPRNLQJLVUHFRUGHGRQWKH0HGLFDO+LVWRU\&5)ZLWKDVWDUWGDWHRQRUEHIRUHILUVWGRVH LHVPRNLQJVWDUWGDWHÂ”GD\RI ILUVW
GRVHDQGDVWRSGDWHRQRUDIWHUILUVWGRVH LHVPRNLQJVWRSGDWHÂ•GD\RI ILUVWGRVH3DUWLDODQG
PLVVLQJGDWHVZLOOEHLPSXWHGXVLQJUXOHVLQ $SSHQGL[ $SSHQGL[ FRQWDLQVDQDWRPLFDO
WKHUDSHXWLFFKHPLFDO$7&FDWHJRULHVDQGGHVFULSWLRQVWKDWZLO OEHXVHGWRLGHQWLI\WUHDWPHQWIRU
K\SHUWHQVLRQ$VXEMHFWLVFRQVLGHUHGWREHUHFHLYLQJWUHDWPHQW IRUK\SHUWHQVLRQDWEDVHOLQHLI
WKHUHLVDWOHDVWWUHDWPHQWIRUK\SHUWHQVLRQZLWKDVWDUWGDW HRQRUEHIRUHILUVWGRVHLH
PHGLFDWLRQVWDUWGDWHÂ”GD\RI ILUVWGRVHDQGDVWRSGDWHRQRUDIWHUILUVWGRVHLHPHGLFDW LRQVWRS
GDWHÂ•GD\RI ILUVWGRVH3DUWLDODQGPLVVLQJGDWHVZLOOEHLPSXWHGXVLQJUX OHVLQ$SSHQGL[ 
&9'FRPSULVHVFRURQDU\GHDWKP\RFDUGLDOLQIDUFWLRQFRURQDU\LQVXIILFLHQF\DQJLQDLVFKHPLFVWURNHKHPRU[LOCATION_006]DJLFVWURNHWUDQVLHQWLVFKHPLFDWWDFNSHULSKHU DODUWHU\GLVHDVHDQGKHDUWIDLOXUH
3OHDVHUHIHUWR $SSHQGL[ IRUWKHVH[VSHFLILFDOJRULWKPVWKDWZLOOEHXVHGWRFRPSXWHH DFK
VXEMHFWÂ¶V)UDPLQJKDP5LVN6FRUHDWEDVHOLQHDQG:HHN 
6DIHW\0HDVXUHV
6DIHW\DQGWROHUDELOLW\PHDVXUHVLQFOXGHDGYHUVHHYHQWV$(V VDIHW\ODERUDWRU\SDUDPHWHUV
FKHPLVWU\KHPDWRORJ\FRDJXODWLRQDQGXULQDO\VLVOHDGH OHFWURFDUGLRJUDPV(&*V
SK\VLFDOH[DPLQDWLRQVYLWDOVLJQVDQGZHLJKW5HJDUGLQJVDIHW \ODERUDWRU\SDUDPHWHUV
SDUWLFXODUDWWHQWLRQZLOOEHSDLGWRKHSDWLFHJDODQLQHDPLQR WUDQVIHUDVH>$/7@DVSDUWDWH
DPLQRWUDQVIHUDVH>$67@ELOLUXELQDONDOLQHSKRVSKDWDVH>$/3@ UHQDOHJEORRGXUHDQLWURJHQ
>%81@VHUXPFUHDWLQLQHSURWHLQFUHDWLQLQHUDWLRDOEXPLQFUHDWLQLQHUDWLRQHXWURSKLOJHODWLQDVHDVVRFLDWHGOLSRFDOLQ>1*$/@XULQDO\VLVVHGLPHQWVS +HOHFWURO\WHVDQGVNHOHWDO
PXVFOHLHFUHDWLQHNLQDVHWR[LFLWLHV$(VZLOOEHFRGHGXVLQ JWKH0HGLFDO'LFWLRQDU\IRU
5HJXODWRU\$FWLYLWLHV0HG'5$YHUVLRQCI
Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 July 2017 
  
 
Confidential Page 14 of 43 7 STUDY POPULATIONS 
7.1 Analysis Populations 
A summary table containing the number of subjects in each of th e populations defined below 
will be provided. 
7.1.1 Full Analysis Set 
The Full Analysis Set (FAS) comprises all randomized subjects w ho receive at least [ADDRESS_739112]-baseline efficacy assessmen t. Subjects will be classified 
according to the treatment they were randomized to. Efficacy an alyses will be conducted using 
the FAS. 7.1.2 Per-Protocol Set 
The Per-Protocol Set (PPS) includes all FAS subjects who comple te the 12-week Treatment 
Period without major protocol dev iations. Subjects will be clas sified according to the treatment 
they were randomized to. The PPS will be determined by [CONTACT_562401]. The PPS will be used to ass ess the robustness of analysis 
results. Subjects excluded from the PPS and the reason for excl usion will be provided in the 
listings. 
 
7.1.3 Safety Analysis Set 
The Safety Analysis Set (SAS) consists of all randomized subjec ts who receive at least 1 dose of 
the study drug. Subjects will be classified according to the tr eatment they actually received. 
Safety analyses will be conducted using the SAS. 

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-[ADDRESS_739113] OR PLANN ED ANALYSES FROM THE 
PROTOCOL 
Although the National Cholesterol Education Program Adult Treatment Panel III 
(NCEP ATP-III) Risk Category was specified in the protocol as a  secondary endpoint, this was 
not computed because the CRFs  did not collect all of the necess ary information (family history 
of premature coronary heart disease).  
Additionally, although the percent of diabetic subjects with > 5% decrease in dosage of anti-
diabetes pharmacologic therapy from baseline to Week 12 was cited in the protocol as an 
exploratory endpoint, this analysis will not be conducted.  
Although the protocol indicates that secondary analyses will be  performed on subjects on and not 
on ezetimibe, these will not be  done due to an insufficient num ber of subjects on ezetimibe. 
Even though confirmatory analyse s for secondary and exploratory  analyses were detailed in the 
protocol, these will not be conducted.  
Additionally, although percent CFBL to Weeks 2, 4, and 8 in LDL -C was not specified in the 
protocol, these analyses will be performed for completeness.  

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 July 2017 
  
 
Confidential Page 16 of 43 9 OVERALL STATISTICAL CONSIDERATIONS 
9.1 Sample Size Computation 
The primary efficacy endpoint is the percent CFBL to Week 12 in  LDL-C, with the primary 
focus on the overall set of randomized subjects. The efficacy w ithin each baseline stable 
statin-intensity (high and moderate) stratum is also of interes t for this study; thus, the study is 
powered for analysis within each baseline statin-intensity stra tum. A sample size of 
26 randomized subjects in the gemcabene 600 mg group and 26 ran domized subjects in the 
placebo group within each baseline statin-intensity stratum is expected to provide 80% power to 
detect a difference of 17% in the percent CFBL to Week [ADDRESS_739114] at the 5% level of significance (alpha = 0.05), a common standard deviation (SD) of 20, a nd a drop-out rate of 10%. The sample size of 26 randomized 
subjects in each baseline statin -intensity stratum in the gemcabene 600 mg group gives a total of 
52 randomized subjects in the gemcabene 600 mg group. Twenty-si x randomized subjects in 
each baseline statin-intensity stratum in the placebo group gives a total of 52 randomized subjects in the placebo group. Thus, the total study sample siz e is 104 randomized subjects. 
9.2 General Conventions 
In general, variables will be summarized using summary statisti cs. Frequency and percentages 
will be used for categorical var iables whereas mean, SD, median, minimum, and maximum will 
be used to summarize continuous  variables. Decimal precision for continuous variables will be 
based on the mean value; the med ian will contain the same numbe r of decimal places as the 
mean, the SD will contain one more decimal place than the mean,  and the minimum and 
maximum will contain one less decimal place than the mean. Typi [INVESTIGATOR_897], the mean will contain 
one more decimal place than actual values but decimal precision  may vary in order to obtain an 
organized and understandable table or listing. 
The first day of administration of randomized study medication (first dose) is defined as 
Study Day 1 or Day 1. All other study days will be computed rel ative to Day 1. For events on or 
after Day 1, study day for a particular event will be calculate d as: 
ÝÝÜ½Ü¦à¯˜à¯©à¯˜à¯¡à¯§àµ†ÝÝÜ½Ü¦ à¯™à¯œà¯¥à¯¦à¯§à¯—à¯¢à¯¦à¯˜ àµ…Í³. For events before Day 1, study day for a particular event wil l be 
calculated as: ÝÝÜ½Ü¦à¯˜à¯©à¯˜à¯¡à¯§àµ†ÝÝÜ½Ü¦ à¯™à¯œà¯¥à¯¦à¯§à¯—à¯¢à¯¦à¯˜ . Day 0 will not be used.  
All statistical testing will be 2 -sided and performed at the al pha = 0.05 level. No multiplicity 
adjustments will be made for testing multiple secondary and exp loratory efficacy outcomes. 
Given the large number of secondary and exploratory efficacy outcomes, p-values associated 
with such outcomes will be considered descriptive. As it is pos sible that some significant results 
could occur due to chance alone, undue consideration will not b e given to isolated significant 
differences; rather, interpretation will be made based on patte rns of significant differences and 
consistency with the primary outcome.  
For a given parameter (eg, y) CFBL will be calculated as Ý•à¯§àµ†Ý•à¯•, where Ý•à¯§ is a given subjectâ€™s  
value t weeks post-baseline and Ý•à¯• is a given subjectâ€™s  value at baseline. CFBL will be computed 

*HPFDEHQH *HPSKLUH7KHUDSHXWLFV,QF
6WDWLVWLFDO$QDO\VLV3ODQ*(0 -XO\
 

&RQILGHQWLDO 3DJHRIIRUVXEMHFWVZLWKDEDVHOLQHYDOXHDQGDSRVWEDVHOLQHYDOXH, QRUGHUWREHLQFOXGHGLQD&)%/
DQDO\VLVIRUDJLYHQSDUDPHWHUDVXEMHFWPXVWKDYHDEDVHOLQH YDOXH,IDVXEMHFWGRHVQRWKDYHD
EDVHOLQHYDOXHWKH\ZLOOEHH[FOXGHGIURPWKH&)%/DQDO\VLV, IDVXEMHFWLVPLVVLQJDSRVW
EDVHOLQHYDOXHODVWREVHUYDWLRQFDUULHGIRUZDUG/2&)ZLOOEHXVHGWRLPSXWHWKHSRVWEDVHOLQH
YDOXHRQO\SRVWEDVHOLQHYDOXHVZLOOEHXVHGIRULPSXWDWLRQ) RUH[DPSOHLIDYDOXHDW:HHNLV
PLVVLQJDQGWKHFRUUHVSRQGLQJ:HHNYDOXHLVQRWPLVVLQJWKH :HHNYDOXHZLOOEHFDUULHG
IRUZDUG&RQVLGHULQJWKDWRQO\SRVWEDVHOLQHYDOXHVFDQEHXVHG IRULPSXWDWLRQLWIROORZVWKHQ
WKDW:HHNVX[COMPANY_003]ULHVZLOORQO\FRQWDLQREVHUYHGFDVHGDWDDVW KHUHZLOOEHQRSRVWEDVHOLQH
YDOXHVWRFDUU\IRUZDUG3HUFHQW&)%/IRUDJLYHQVXEMHFWDQGS DUDPHWHUZLOOEHFRPSXWHGDV
á‰€à¯¬à³Ÿà¬¿à¯¬à³
à¯¬à³á‰×›Í³Í²Í²LH&)%/GLYLGHGE\WKHEDVHOLQHYDOXHDQGPXOWLSOLHGE\ 3HUFHQW&)%/
ZLOORQO\EHFRPSXWHGIRUVXEMHFWVZLWKD&)%/YDOXH$GGLWLRQD OO\VXEMHFWVZLWKDYDOXHRIDW
EDVHOLQHZLOOQRWKDYHSHUFHQW&)%/FRPSXWHG
)RUHIILFDF\SDUDPHWHUVHQGRIWUHDWPHQWLVGHILQHGDVWKHODVWQRQPLVVLQJSRVWEDVHOLQHYDOXH
FROOHFWHGZKLOHRQWUHDWPHQWRUZLWKLQGD\VRIWUHDWPHQWODV WGRVHIRUDJLYHQVXEMHFW)RU
VDIHW\SDUDPHWHUVHQGRIWUHDWPHQWLVGHILQHGDVWKHODVWQRQ PLVVLQJSRVWEDVHOLQHYDOXH
FROOHFWHGZKLOHRQWUHDWPHQWRUZLWKLQGD\VRIWUHDWPHQWODV WGRVH
7KHSULPDU\HIILFDF\DQDO\VLVZLOOEHFRQGXFWHGXVLQJDQDO\VLV RIFRYDULDQFH$1&29$
6HFRQGDU\DQGH[SORUDWRU\DQDO\VHVZLOOXWLOL]HDVLPLODUDSSURDFKH[FHSWZKHQWKHRXWFRPHRI
LQWHUHVWLVELQDU\ZKHQWKHRXWFRPHRILQWHUHVWLVELQDU\DORJLVWLFUHJUHVVLRQZLOOEHSHUIRUPHG
%DVHOLQH'HILQLWLRQV
%DVHOLQHIRUDJLYHQSDUDPHWHULVJHQHUDOO\GHILQHGDVWKHODVW DVVHVVPHQWSULRUWRWKHILUVWGRVH
RIWKHVWXG\GUXJEXWYDULHVGHSHQGLQJRQWKHSDUDPHWHU
Â‡%DVHOLQHIRUOLSLGVLH/'/&QRQ+'/&7&7*+'/&DQG9/ '/&LVGHILQHGDVWKH
DYHUDJHRI WKHFRUUHVSRQGLQJSDUDPHWHUÂ¶V ODVWQRQPLVVLQJYDOXHVEHWZHHQDQGLQFOXGLQJ
6FUHHQLQJDQGSUHGRVH'D\,IRQO\YDOXHLVDYDLODEOHLW ZLOOEHXVHGIRUEDVHOLQH
Â‡%DVHOLQHIRUDSROLSRSURWHLQVLH$SR%$SR$,$SR$,,$SR$9 $SR&,,$SR&,,,
$SR(DQG/S>D@LQIOD[COMPANY_003]WRU\ELRPDUNHUVLHKV&536$$DGLS RQHFWLQDQGILEULQRJHQ
VHUXP IDVWLQJLQVXOLQ DQG)3*LVGHILQHGDVWKHFRUUHVSRQGLQJSDUDPHWHUÂ¶V ODVWQRQ
PLVVLQJYDOXHEHWZHHQDQGLQFOXGLQJ6FUHHQLQJDQGSUHGRVH'D \
Â‡%DVHOLQHIRU+E$FLVGHILQHGDVWKHYDOXHIURPWKHILUVWYLVLW3UH6FUHHQLQJRU6FUHHQLQJ
9LVLW
Â‡%DVHOLQHIRU(&*VYLWDOVLJQVERG\PDVVLQGH[%0,ZHLJKW DQGVDIHW\ODERUDWRU\
SDUDPHWHUVLHFKHPLVWU\KHPDWRORJ\FRDJXODWLRQDQGXULQDO\ VLVSDUDPHWHUVLVGHILQHGDV
WKHODVWSUHGRVHPHDVXUHPHQWSUHGRVH6WXG\'D\RUEHIRUH IRUWKHFRUUHVSRQGLQJ
SDUDPHWHU
Â‡%DVHOLQH)UDPLQJKDP5LVN6FRUHIRUHDFKVXEMHFWZLOOEHFRPSXWH GXVLQJWKHIROORZLQJ
YDULDEOHVDWWKHIROORZLQJWLPHSRLQWVDJHDWWKH6FUHHQLQJ9LVLWEDVHOLQH7&SUHYLRXVO\GHILQHGEDVHOLQH+'/&EDVHOLQH6%3WUHDWPHQWIRUK\SHUWHQV LRQDW'D\VPRNLQJVWDWXV
DW'D\DQGGLDEHWHVVWDWXVDWWKH6FUHHQLQJ9LVLWCI
*HPFDEHQH *HPSKLUH7KHUDSHXWLFV,QF
6WDWLVWLFDO$QDO\VLV3ODQ*(0 -XO\
&RQILGHQWLDO 3DJHRI+DQGOLQJRI0LVVLQJ'DWD
0LVVLQJYDOXHVDWEDVHOLQHZLOOQRWEHLPSXWHGLQDQ\VLWXDWLRQ)RUHIILFDF\DQDO\VHVYDOXHV
PLVVLQJSRVWUDQGRPL]DWLRQZLOOEHLPSXWHGXVLQJ/2&)XQOHVVR WKHUZLVHVSHFLILHGRQO\
SRVWUDQGRPL]DWLRQYDOXHVRQWUHDWPHQWZLOOEHXVHGIRULPSXWDW LRQ)RUH[DPSOHLIDVXEMHFWKDV
:HHNHIILFDF\SDUDPHWHUVPHDVXUHGPRUHWKDQGD\VDIWHUWKH LUODVWGRVHWKHLU:HHN
HIILFDF\YDOXHVZLOOEHLPSXWHGXVLQJWKHODVWQRQPLVVLQJYDOX HZKLOHRQWUHDWPHQWHJ
:HHN7KHLPSXWHGYDOXHVZLOOEHXVHGLQVX[COMPANY_003]ULHVDQGDQDO\ VLV)RUVDIHW\DQDO\VHV
REVHUYHGFDVHGDWDZLOOEHXVHG
,PSXWDWLRQZLOOQRWEHFRQGXFWHGIRU$(VPLVVLQJVHYHULW\RUUH ODWLRQVKLSWRVWXG\PHGLFDWLRQ
$(VPLVVLQJVHYHULW\ZLOOEHH[FOXGHGIURPVX[COMPANY_003]ULHVRI$(VE\ VHYHULW\$GYHUVHHYHQWV
PLVVLQJUHODWLRQVKLSZLOOEHH[FOXGHGIURPVX[COMPANY_003]ULHVRIUHODWHG $(V
5XOHVIRUSDUWLDODQGPLVVLQJGDWHVIRUSULRUDQGFRQFRPLWDQWP HGLFDWLRQVDQGVPRNLQJVWDWXVDUH
JLYHQLQ$SSHQGL[ 
'UXJLQWHUUXSWLRQVZLWKSDUWLDOVWDUWDQGRUVWRSGDWHVZLOOEH DVVXPHGWREHGD\LQOHQJWKDQG
ZLOOEHDVVXPHGWRKDYHRFFXUUHGLQWKHYLVLWLQWHUYDOSULRUWRZKHQWKHLQWHUUXSWLRQZDVFROOHFWHG
HJLIDGUXJLQWHUUXSWLRQZLWKSDUWLDOGDWHVZDVFROOHFWHGDW WKH:HHNYLVLWZHZLOODVVXPH
WKDWWKHLQWHUUXSWLRQRFFXUUHGEHWZHHQWKHSUHYLRXVYLVLW>HJ:HHN@DQGWKH:HHNYLVLW
,QWHULP$QDO\VLV
7KHUHLVQRSODQQHGLQWHULPDQDO\VLV
9LVLW:LQGRZV
9LVLWZLQGRZVZLOOEHXVHGWRFODVVLI\VFKHGXOHGH[FHSWWKH)R OORZXS9LVLWXQVFKHGXOHGDQG
HDUO\WHUPLQDWLRQ(7YLVLWVDFFRUGLQJWR 7DEOHEHORZWRHQVXUHWKDWDOOYLVLWVKDYHWKH
SRWHQWLDOWRFRQWULEXWHWRVX[COMPANY_003]ULHV,IRUPRUHYLVLWVRFFXUZLWKLQWKHVDPHDQDO\VLVZLQGRZ
GDWDIURPWKHYLVLWFORVHVWWRWKHWDUJHWGD\ZLOOEHXVHGLQVX[COMPANY_003]ULHVDQGRUDQDO\VLVLIWKHYLVLWVDUHWKHVDPHGLVWDQFHIURPWKHWDUJHWGD\GDWDIURPWKHODWHU GDWHZLOOEHXVHG'DWDIRU
ODERUDWRU\SDUDPHWHUVVFKHGXOHGWREHPHDVXUHGSRVWUDQGRPL]DWLRQDWRQO\WKH:HHNRU(79LVLWLH+E$F KV&536$$ILEULQRJHQDGLSRQHFWLQ)3*DQ GLQVXOLQZLOOEH
VX[COMPANY_003]UL]HGXQGHUWKH:HHN9LVLW,IWKHUHLVPRUHWKDQRQHYDOXHWKHODWHVWZLOOEHXVHG)RUHIILFDF\SDUDPHWHUVPHDVXUHGDIWHUODVWGRVHGD\VZLOOQRWEHFRQVLGHUHG([FHSWIRUDGYHUVHHYHQWVIRUVDIHW\SDUDPHWHUVPHDVXUHGDIWHUODVWGRVH GD\VZLOOQRWEHFRQVLGHUHGCI
Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 July 2017 
  
 
Confidential Page 19 of 43 Table 2. Visit Windows for Assessments Done at Day 1, Weeks 2, 4, 8, and 12a 
Visit Target Study Day Visit Window 
Day 1 1 (1) 
Week 2 15 (2, 22) 
Week 4 29 (23, 43) 
Week 8 57 (44, 71) 
Week 12 85 > [ADDRESS_739115] urinalysis parameters are not measured at Wee k 2, the Visit Window for 
Week 4 for Apo and urinalysis parameters is (2, 43). Remaining urinalysis parameters are not 
measured at Week 2 or Week 8; thus, the Visit Windows for Week 4 and Week 12 are (2, 57) 
and > 57, respectively. 
 

*HPFDEHQH *HPSKLUH7KHUDSHXWLFV,QF
6WDWLVWLFDO$QDO\VLV3ODQ*(0 -XO\
 

&RQILGHQWLDO 3DJHRI10STATISTICAL ANALYSIS METHODS 
6XEMHFW'LVSRVLWLRQ
7KHQXPEHURIVXEMHFWVVFUHHQHGUHDVRQVIRUVFUHHQIDLOXUHDQ GWKHQXPEHURIVXEMHFWV
UDQGRPL]HGZLOOEHVX[COMPANY_003]UL]HGIRUDOOVFUHHQHGVXEMHFWV1XPEHU RIVXEMHFWVZKRFRPSOHWHDQG
GLVFRQWLQXHWKHVWXG\DQGUHDVRQVIRUVWXG\GLVFRQWLQXDWLRQWKDWRFFXUSRVWUDQGRPL]DWLRQZLOO
EHVX[COMPANY_003]UL]HGE\UDQGRPL]HGWUHDWPHQWJURXSLHSODFHERDQGJH PFDEHQHPJIRUWKH
)$65HDVRQVIRUGLVFRQWLQXDWLRQZLOOEHFDWHJRUL]HGXVLQJWKH UHDVRQVSURYLGHGRQWKH&5)LH
$(SURKLELWHGPHGLFDWLRQQRQFRPSOLDQFHZLWKGUDZDOE\VXEMHF WORVWWRIROORZXSGHDWK
WHUPLQDWLRQE\VSRQVRUDQGRWKHUUHDVRQV$GGLWLRQDOO\SURWRFROGHYLDWLRQVZLOOEHOLVWHGIRUDOOUDQGRPL]HGVXEMHFWV
'HPRJUDSKLFVDQG%DVHOLQH&KDUDFWHULVWLFV
'HPRJUDSKLFLQIRUPDWLRQZLOOEHVX[COMPANY_003]UL]HGXVLQJGHVFULSWLYHVW DWLVWLFVE\UDQGRPL]HG
WUHDWPHQWJURXSDQGRYHUDOOIRUWKH)$6$GGLWLRQDOO\GHPRJUDSKLFLQIRUPDWLRQZLOOEHSUHVHQWHGE\VWDWLQLQWHQVLW\VWUDWXPPRGHUDWHDQGKLJKIRU GLDEHWLFVXEMHFWVDQGIRUVXEMHFWV
ZLWKDQGZLWKRXWPL[HGG\VOLSLGHPLD([SOLFLWO\WKHIROORZLQJ FKDUDFWHULVWLFVZLOOEH
VX[COMPANY_003]UL]HG
Â‡6H[0DOH)HPDOH
Â‡0HQRSDXVDO6WDWXVIRU)HPDOHVSRVWPHQRSDXVDORUVXUJLFDOO\VW HULOHSUHPHQRSDXVDO
Â‡5DFH:KLWH%ODFNRU$IULFDQ$PHULFDQ$VLDQ$PHULFDQ,QGLDQRU$ODVND1DWLYH1DWLYH
+DZDLLDQRU2WKHU3DFLILF,VODQGHU2WKHU
Â‡(WKQLFLW\+LVSDQLFRU/DWLQR1RW+LVSDQLFRU/DWLQR8QNQRZQ 
Â‡$JH
Â‡+HLJKW
Â‡:HLJKWDQG
Â‡%0,
ZKHUHDJHZLOOEHFRPSXWHGIRUHDFKVXEMHFWXVLQJWKHIROORZLQJ IRUPXOD
$JH LQWHJHU>6FUHHQLQJ9LVLWGDWHÂ±GDWHRIELUWK@
DQG%0,ZLOOEHFDOFXODWHGXVLQJWKHIROORZLQJIRUPXOD
%0, ERG\ZHLJKWLQNLORJUDPVKHLJKWLQPHWHUV

3UHJQDQF\WHVWUHVXOWVZLOOEHOLVWHGIRUIHPDOHVXEMHFWV
$GGLWLRQDOO\EDVHOLQHSULPDU\DQGVHFRQGDU\HQGSRLQWVDORQJZL WKH[SORUDWRU\HQGSRLQW
ZLOOEHVX[COMPANY_003]UL]HGIRUWKH)$6E\UDQGRPL]HGWUHDWPHQWJURXSDQ GRYHUDOO
6SHFLILFDOO\WKHIROORZLQJSDUDPHWHUVZLOOEHVX[COMPANY_003]UL]HGDWED VHOLQHOLSLGVDSROLSRSURWHLQV
LQIOD[COMPANY_003]WRU\ELRPDUNHUVDQGWKH)UDPLQJKDP5LVN6FRUH7KLVWD EOHZLOOWKHQEHUHSHDWHGIRUCI
Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 July 2017 
  
 
Confidential Page 21 of 43 each baseline statin-intensity stratum (moderate, high). Additionally, the number and percentage 
of diabetic subjects and subjects on and not on ezetimibe in ea ch of the previously mentioned 
groups will be summarized for the FAS. A subject on ezetimibe i s defined as a subject with 
ezetimibe recorded on the Concomitant Medications CRF with a st art date on or before first dose 
(ie, medication start date â‰¤ day of first dose) and a stop date on or after first dose (ie, medication 
stop date â‰¥ day of first dose). Partial and missing dates will be imputed using rules in Appendix 
2.  
Further, for the subgroup of diabetic subjects within the FAS, baseline fasting insulin, FPG, 
HbA1c, lipi[INVESTIGATOR_805], apolipoproteins, a nd inflammatory biomarkers wil l be summarized by 
[CONTACT_303447].  
Lastly, for the subgroup of subjects with mixed dyslipi[INVESTIGATOR_562396], baseline 
lipi[INVESTIGATOR_805], apolipoproteins, and inflam matory biomarkers will be su mmarized by [CONTACT_562402]. Thi s table will then be repeated for the subgroup of subjects without 
mixed dyslipi[INVESTIGATOR_562397].  
For categorical parameters, denominators for percentages will b e the number of subjects in the 
corresponding group (eg, gemcabene 600 mg) with non-missing dat a for the parameter of 
interest. 
10.[ADDRESS_739116]-randomizatio n visit during the treatment 
period (and the ET visit, if appli cable), where treatment perio d is defined as the time period 
bounded by [CONTACT_562403], as (number of tablets taken since last visit/number of tablets that should have been taken since last visit)*100. As each subject is 
instructed to take [ADDRESS_739117] visit will be computed as 3 tabl ets per day*number of days since 
last visit, where the number of days since the last visit will be computed as (day of visit - day of 
last visit + 1). Compliance will  be summarized by [CONTACT_562404].  
For each subject, overall compliance will be computed as (numbe r of tablets taken during 
treatment period/number of table ts that should have been taken during treatment period)*100. 
The number of tablets that should have been taken during the treatment period will be computed as 3 tablets per day* number of days during the treatment period, where the number of days during the treatment period will  be computed as (last dose date  â€“ first dose date + 1). Subjects 
will then be grouped into categor ies of overall compliance (< 80%, 80% to 100%) according to 
their overall estimate of compliance. Overall compliance and ca tegories of compliance will be 
summarized using descriptive s tatistics by [CONTACT_562405].  

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-[ADDRESS_739118] as (la st dose date â€“ first dose date + 1) 
and will be summarized using descriptive statistics. The number of subjects who receive â‰¥ 1 day, 
â‰¥ 7 days, â‰¥  14 days , â‰¥ 28 days, â‰¥  42 days, â‰¥  56 days, â‰¥ 70 days, and â‰¥ 84 days of the study 
medication will be presented by [CONTACT_562406]. 
Days on treatment will be computed as the number of days that t he study medication was taken 
(ie, treatment exposure excluding days when the study medicatio n was interrupted). Number of 
days on treatment and number of days study medication was inter rupted for will be summarized 
for the SAS.  

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 July 2017 
  
 
Confidential Page 23 of 43 11 EFFICACY PARAMETERS 
11.1 Primary Analysis  
The primary efficacy endpoint (percent CFBL to Week 12 in LDL-C ) will be analyzed using 
ANCOVA and the FAS population. The null hypothesis to be tested  is that there is no difference 
in the expected percent CFBL to Week 12 in LDL-C between the ac tive treatment (subjects 
treated with gemcabene 600 mg) and placebo (subjects treated with placebo) groups after 
adjusting for baseline statin-intensity stratum, baseline diabe tes status, and baseline LDL-C. 
Explicitly, in the ANCOVA, percent CFBL to Week 12 in LDL-C wil l be the dependent variable 
whereas randomized treatment group (gemcabene 600 mg or placebo ), baseline statin-intensity 
stratum (moderate or high), and ba seline diabetes status (yes o r no) will be included as factors, 
and baseline LDL-C will be include d as a covariate. LOCF will be used to impute missing values 
for Week 12; only post-baseline va lues will be used for imputat ion. The least-squares mean 
(LSM) and standard error (SE) for percent CFBL to Week [ADDRESS_739119]-squares mean and 95% confidence interval (CI) of the treatment difference will be 
produced from the model using type III sums of squares to estim ate the magnitude of the 
treatment effect. The following SAS code will be used to conduc t the ANCOVA: 
proc glm data= data; 
    class Drug(ref=â€Placeboâ€) Diabetes StatinStrat; 
    model pctCFBL = Drug Diabetes StatinStrat Base / solution; 
    lsmeans Drug / stderr pdiff out=adjmeans; run; 
The following additional analyses will be performed to assess a ssumptions of ANCOVA. The 
assumptions of normality and homosced asticity (equal variance) will be assessed using residuals 
from the ANCOVA. Explicitly, normality will be assessed by [CONTACT_562407]-quantile plots and conduc ting the Shapi[INVESTIGATOR_2152]-Wilk test. I f normality is clearly violated, 
ranked ANCOVA will be conducted. Further, Leveneâ€™s test will be  conducted and residual plots 
will be visually assessed to determine if the assumption of hom oscedasticity is met. Lastly, we 
will investigate the assumption of homogeneity of regression sl opes across treatment groups 
(parallel slopes) by [CONTACT_562408]-C and treatment group in the 
model explicated previously. If  results indicate that the interaction between baseline LDL-C and 
treatment group is not significant , we will assume that the ass umption of parallel slopes is met. If 
the assumption of homoscedasticity  or parallel slopes is clearl y violated, the final model may be 
adjusted.  
Confirmatory analysis will be conducted by [CONTACT_562409].  
11.2 Secondary Analysis 
All secondary analyses will be conducted using the FAS populati on (or the specific subgroup 
within the FAS population, eg, diabetic subjects) with subjects  included in their randomized 
treatment group regardless of the treatment they actually recei ved.  

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-[ADDRESS_739120] (eg, if the parameter of interest 
is HDL-C, the covariate in the ANCOVA will be HDL-C at baseline ). 
As previous research suggests that hsCRP and TG are non-normall y distributed, 3, 4, 5, hsCRP and 
TG will be analyzed using ranked ANCOVA. [ADDRESS_739121] 
ranking the outcome and covariate at a given timepoint (eg, Wee k 12) prior to conducting 
ANCOVA. The p-value corresponding to the difference in ranked o utcome between treatment 
groups will be output, and results will be interpreted in the c ontext of the median change from 
baseline for each treatment g roup. The SAS code for conducting ranked ANCOVA is provided 
below (this can be extended to percent change from baseline): 
proc rank data= data out= data_rank  ties=mean;  
 var base chg;  
 ranks r_base r_chg;  
run; 
 
proc glm data= data_rank ; 
 class Drug(ref=â€Placeboâ€) Diabetes StatinStrat ; 
 model r_chg = Drug Diabetes StatinStrat  r_base / solution;   
 lsmeans Drug / stderr pdiff cl out=adjmeans; 
quit; 
 
 The secondary efficacy endpoints that are binary will be analy zed using logistic regression. The 
output from each logistic regression model will include the odds ratio (OR), 95% CI, and the 
associated p-value. The SAS code for conducting a logistic regr ession model is provided below: 
 
proc logistic data= data; 
class Drug(ref=â€Placeboâ€) Diabetes StatinStrat; 
model Outcome(event=â€ eventâ€)= Drug Diabetes StatinStrat Base / expb; 
run;  
The secondary efficacy analyses are: 
â€¢ percent CFBL to Week 12 in LDL-C within each statin-intensity s tratum (moderate, high); 
â€¢ CFBL to Weeks 2, 4, 8, and 12 in LDL-C; 
â€¢ percent CFBL to Weeks 2, 4, and 8 in LDL-C; 
â€¢ CFBL and percent CFBL to the a verage of Weeks 8 and 12 in LDL-C; 
â€¢ CFBL and percent CFBL to Weeks 2, 4, 8, and 12 in non-HDL-C, TC , TG, HDL-C, and 
VLDL-C; 
â€¢ percent of subjects achieving a LDL- C reduction of â‰¥ 10%, â‰¥  15%, and â‰¥ 20% at Weeks  4, 8, 
and 12 (separately); 
â€¢ percent of subjects achieving a LDL-C value < 100 mg/dL (2.59 m mol/L) at Weeks 4, 8, and 
12 (separately); 

*HPFDEHQH *HPSKLUH7KHUDSHXWLFV,QF
6WDWLVWLFDO$QDO\VLV3ODQ*(0 -XO\
 

&RQILGHQWLDO 3DJHRIÂ‡&)%/DQGSHUFHQW&)%/WR:HHNVDQGLQ$SR%$SR$,$SR $,,$SR$9
$SR&,,$SR&,,,$SR(DQG/SD
Â‡&)%/DQGSHUFHQW&)%/WR:HHNLQKV&536$$DGLSRQHFWLQDQ GILEULQRJHQDQG
Â‡&)%/WR:HHNLQ)UDPLQJKDP5LVN6FRUH
3HUFHQW&)%/WR:HHNLQ/'/&ZLWKLQHDFKVWDWLQLQWHQVLW\V WUDWXPPRGHUDWHDQGKLJK
ZLOOEHDQDO\]HGXVLQJWKHVDPHDSSURDFKDVWKHSULPDU\DQDO\VL VH[FHSWWKDWEDVHOLQH
VWDWLQLQWHQVLW\VWUDWXPZLOOQRWEHLQFOXGHGLQWKHPRGHO
&)%/WR:HHNVDQGLQ/'/&SHUFHQW&)%/WR:HHNV DQGLQ/'/&DQG
&)%/DQGSHUFHQW&)%/WRWKHDYHUDJHRI:HHNVDQGLQ/'/& ZLOOEHDQDO\]HGXVLQJWKH
VDPHDSSURDFKDVWKHSULPDU\DQDO\VLV
&)%/DQGSHUFHQW&)%/WR:HHNVDQGLQQRQ+'/&7& 7*+'/&DQG
9/'/&&)%/DQGSHUFHQW&)%/WR:HHNVDQGLQ$SR%$SR $,$SR$,,$SR$9
$SR&,,$SR&,,,$SR(DQG/SDDQG&)%/DQGSHUFHQW&)%/WR:HHNLQKV&536$$
DGLSRQHFWLQDQGILEULQRJHQZLOOEHDQDO\]HGXVLQJWKHVDPHDSS URDFKDVWKHSULPDU\DQDO\VLV
H[FHSWWKDWKV&53DQG7*ZLOOEHDQDO\]HGZLWKUDQNHG$1&29$
3HUFHQWRIVXEMHFWVDFKLHYLQJDQ/'/ &UHGXFWLRQRIÂ•Â•DQGÂ•DW:HHNV
DQGFRPSDUHGWREDVHOLQHDQGSHUFHQWRIVXEMHFWVDFKLHYLQJDQ/'/&YDOXHPJG/
PPRO/DW:HHNVDQGFRPSDUHGWREDVHOLQHZLOO EHDQDO\]HGXVLQJORJLVWLF
UHJUHVVLRQ([SOLFLWO\ZHZLOOHVWLPDWHWKHRGGVRIDFKLHYLQJ WKHFRUUHVSRQGLQJUHGXFWLRQ
LHÂ•Â•DQGÂ• RUDQ/'/&YDOXHPJG/DWDJLYHQZHHNXVLQJORJLVWLF
UHJUHVVLRQ5DQGRPL]HGWUHDWPHQWJURXSJHPFDEHQHPJRUSOD FHEREDVHOLQH
VWDWLQLQWHQVLW\VWUDWXPPRGHUDWHRUKLJKLQWHQVLW\GLDEHWH VVWDWXV\HVRUQRDQGEDVHOLQH
/'/&ZLOOEHLQFOXGHGLQHDFKPRGHODVIDFWRUV
)UDPLQJKDP5LVN6FRUHDWEDVHOLQHDQG:HHNDORQJZLWK&)%/LQ)UDPLQJKDP5LVN6FRUH
WR:HHNZLOOEHVX[COMPANY_003]UL]HGE\UDQGRPL]HGWUHDWPHQWJURXSXVLQJGHVFULSWLYHVWDWLVWLFV)UDPLQJKDP5LVN6FRUHDWEDVHOLQHKDVEHHQH[SOLFDWHGSUHYLRXVO \)UDPLQJKDP5LVN6FRUHDW
:HHNZLOOEHFRPSXWHGIRUHDFKVXEMHFWXVLQJWKHIROORZLQJY DULDEOHVDWWKHIROORZLQJWLPH
SRLQWVDJHDWWKH6FUHHQLQJ9LVLW7&DW:HHN+'/&DW:HH N6%3DW:HHN
WUHDWPHQWIRUK\SHUWHQVLRQDW:HHNVPRNLQJVWDWXVDW'D\ DQGGLDEHWHVVWDWXVDWWKH
6FUHHQLQJ9LVLW$VXEMHFWLVFRQVLGHUHGWREHUHFHLYLQJWUHDWP HQWIRUK\SHUWHQVLRQDW:HHNLI
WKHUHLVDWOHDVWRQHWUHDWPHQWIRUK\SHUWHQVLRQZLWKDVWDUWGDWHRQRUEHIRUHWKHLU:HHN9LVLW
ODVWGRVH LHPHGLFDWLRQVWDUWGDWHÂ”GD\RI ODVWGRVHDQGDVWRSGDWHRQRUDIWHUWKHLU:HHN
9LVLWODVWGRVHLHPHGLFDWLRQVWRSGDWHÂ•GD\RI ODVWGRVH3DUWLDODQGPLVVLQJGDWHVZLOOEH
LPSXWHGXVLQJUXOHVLQ$SSHQGL[ 
([SORUDWRU\$QDO\VLV

CI
*HPFDEHQH *HPSKLUH7KHUDSHXWLFV,QF
6WDWLVWLFDO$QDO\VLV3ODQ*(0 -XO\
 

&RQILGHQWLDO 3DJHRI

 
 

 

 

 

 
















0DQXVFULSW$QDO\VLV
3OHDVHUHIHUWR $SSHQGL[ IRUDGGLWLRQDODQDO\VHVWKDWZLOOEHSHUIRUPHGIRULQFOXVLRQL QD
PDQXVFULSW)XUWKHUSOHDVHQRWHWKDWUHVXOWVRIWKHVHDQDO\VHV ZLOOQRWEHSUHVHQWHGLQWKHFOLQLFDO
VWXG\UHSRUWCI
Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-[ADDRESS_739122] actually rece ived regardless of the treatment 
group they were randomized to. All safety data will be presente d in listings. 
12.1 Adverse Events 
AEs will be coded using MedDRA version 19.1. Except for the AE overview table and 
summaries of serious adverse eve nts (SAEs) and AEs resulting in  death (both of which will 
include all AEs), AE tables w ill only include summaries of trea tment-emergent adverse events 
(TEAEs). A TEAE is defined as a n AE with a start date on or aft er the first dose date and less 
than [ADDRESS_739123] dose date. If the AE start date is missing, the AE is assumed to be a 
TEAE. An AE overview table contain ing the frequency and percent  of the following will be 
summarized by [CONTACT_1570], treatment group within each stratum, and treatment group 
within each statin type (atorvastatin, rosuvastatin, simvastati n): 
â€¢ Number of subjects with at least one TEAE, drug-related TEAE, S AE, and drug-related SAE; 
â€¢ Number of subjects who discontinued study treatment due to a TE AE, drug-related TEAE, 
SAE, and drug-related SAE;  
â€¢ Number of subjects who had a study treatment interruption due to a TEAE; 
â€¢ Number of subjects who discontinued the study due to a TEAE; an d  
â€¢ Number of deaths and deaths due to a drug-related TEAE.  
Additionally, the following will be summarized by [CONTACT_17673], and treatment group within 
each stratum: 
â€¢ TEAEs by [CONTACT_9313] (SOC) and preferred term (PT); 
â€¢ TEAEs by [CONTACT_6214] (decreasing freque ncy in the gemcabene group); 
â€¢ TEAEs by [CONTACT_2946], PT, and maximum severity; 
â€¢ Related TEAEs by [CONTACT_3592]; 
â€¢ Related TEAEs by [CONTACT_6214] (decreasing f requency in the gemcabene grou p); 
â€¢ SAEs by [CONTACT_3592]; 
â€¢ Related SAEs by [CONTACT_3592]; 
â€¢ Discontinuation of study treatme nt due to TEAEs by [CONTACT_3592]; 
â€¢ Discontinuation of study treatme nt due to related TEAEs by [CONTACT_3592]; and 
â€¢ AEs that resulted in death by [CONTACT_3592]. 
Summaries of SOC and PT will be s orted alphabetically by [CONTACT_562410]. 

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-[ADDRESS_739124] has more than 1 TEAE at a given level (eg, SOC and PT), the subject will only be 
counted once within that level. When summarizing TEAEs by [CONTACT_562411], at 
each level of summarization, subj ects who report [ADDRESS_739125] severity  (in severity tables) or strongest 
relationship to study drug (in causality tables). All tables wi ll show the number and percent of 
subjects with at least 1 TEAE (or SAE, per the criteria on the table). For example, the table of 
related SAEs will include a row for number and percent of subje cts with at least one related 
SAE. Additionally, a drug-related TEAE is defined as a TEAE wit h an assigned relationship of 
â€œrelated. â€ A listing containing all AEs (pre-treatment and TEAEs) will be created; AEs that are 
not treatment-emergent will be flagged as non-treatment-emergen t. Additionally, a listing 
containing AEs missing severity or relationship to the study drug will be provided; AEs that are not treatment-emergent will be flagged as non-treatment-emergen t. 
12.[ADDRESS_739126] clinical laboratory evaluations for safety chemistry, coagulation, and hematology will  
be conducted at all study visits and the Follow-up Visit (only for subjects who had an abnormal 
result at Week 12 [or the ET Visit, if applicable] or an ongoin g treatment-related AE). Clinically 
significant abnormal creatinine results at Week 12 (or the ET V isit, if applicable) will also be 
followed-up 2 weeks (Â± 3 days) after the last dose of study drug in addition to the 4 week (Â± 3 days) Follow-up Visit.  
Additionally, a urine sample for urinalysis will be collected a t the Pre-Screening Visit, if 
applicable, the Screening Visit, Day 1, Week 4, Week 8, Week 12 , the Follow-up Visit (only for 
subjects who had an abnormal resu lt at Week 12 [or the ET Visit, if applicable] or an ongoing 
treatment-related AE), and the ET Visit, if applicable. A urine  microscopic examination will be 
performed when the dipstick result is abnormal (positive for bl ood, leukocyte esterase, or 
nitrites). Urine protein/creatinine ratio and albumin/creatinin e ratio will be performed at the 
Screening Visit, Day 1, Week 4, Week 12, the Follow-up Visit (o nly for subjects who had an 
abnormal result at Week 12 [or t he ET Visit, if applicable] or an ongoing treatment-related AE), 
and the ET Visit, if applicable. Urinary NGAL will be measured at Day 1, Week 4, Week 12, the 
Follow-up Visit (only for subjects who had an abnormal result a t Week 12 [or the ET Visit, if 
applicable] or an ongoing treatment-related AE), and the ET Visit, if applicable. 
The following laboratory parameters will be summarized at basel ine and at each post-baseline 
time point by [CONTACT_1570]. Additionally, CFBL to each time point (including end of 
treatment), if appropriate, for each of the following laborator y parameters will also be 
summarized by [CONTACT_1570]. If, for a given subject at a giv en visit, the absolute count of 
neutrophils are not provided but s egmented and band neutrophils  are, segmented and band 
neutrophils are summed to determi ne the absolute count of neutr ophils. If only segmented 
neutrophils are provided, they are used as the absolute count o f neutrophils. Similarly, if 
neutrophils/leukocytes are not provided at a given visit but ne utrophils (segmented)/leukocytes 
are, neutrophils (segmented)/leukocytes are used as neutrophils /leukocytes. If a laboratory value 
is lower or higher than the detection limit, the value will not  contribute to summary statistics but 
will be included in the listings.  

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 July 2017 
  
 
Confidential Page 29 of 43 â€¢ Chemistry: ALT, albumin, ALP , AST, bicarbonate, BUN, calcium, c hloride, 
creatine kinase (CK), creatinine, gamma-glutamyl transferase (G GT), glucose, lactate 
dehydrogenase (LDH), phosphorus, potassium, sodium, (total) bil irubin, (total) protein, 
estimated glomerular filtration rate (GFR) 
â€¢ Coagulation: prothrombin time, activated partial thromboplastin  time, international 
normalized ratio 
â€¢ Hematology: hemoglobin, hematocrit, leukocytes, basophils, eosinophils, lymphocytes, 
monocytes, neutrophils, platelets, red blood cell count, mean corpuscular hemoglobin 
concentration, mean corpuscula r hemoglobin, mean corpuscular vo lume 
â€¢ Urinalysis: pH, specific gravity, NGAL, creatinine, protein, pr otein/creatinine ratio, albumin, 
albumin/creatinine ratio 
Out-of-range values will be assesse d using shift tables. Labora tory values will be identified as 
low, normal, or high based on the normal ranges provided by [CONTACT_399876]. Shift tables 
for each parameter will display, for each treatment group, the number of subjects with low, normal, and high values at baseline and end of treatment. Addit ionally, a summary will be 
provided of the number of subjects who shifted to high or low during the study. The denominators will be the number of subjects at risk for shiftin g, ie, the subjects at risk for 
shifting to low are those with high or normal values at baselin e, and the subjects at risk for 
shifting to high are those with low or normal values at baselin e.  
Potentially clinically significant (PCS) tables will also be us ed to summarize out-of-range values 
for safety laboratory parameters. The PCS values are found in Table 3. The number and percent 
of subjects meeting the criteria below for single occurrences a nd consecutive (multiple) 
occurrences will be summarized by [CONTACT_1570]. The number a nd percent of subjects 
meeting the criteria below for single occurrences will be repea ted for each statin-intensity 
stratum. Summaries will be give n for any time post-baseline. Th e denominator for a given 
percentage will be the number of subjects who had a post-baseli ne assessment for the 
corresponding parameter. Additionally, for subjects with at lea st [ADDRESS_739127]-baseline laboratory value 
meeting the PCS criteria, all laboratory values will be provide d in a listing.  
Table 3. Lab PCS Criteria 
Laboratory Parameter Unit PCS Criteria 
ALT U/L > 2 Ã— ULN 
AST U/L > 2 Ã— ULN 
BUN mg/dL > 2 Ã— ULN 
Creatine kinase U/L > 3 Ã— ULN 
Creatinine mg/dL > 0.3 increase from baseline 
Estimated GFR mL/min Decrease > 15 from baseline 
Hemoglobin g/dL Decrease > 1.5 from baseline 
Urinalysis Parameter Unit PCS Criteria 
Blood - present 
Protein (qualitative) - present 
Protein (quantitative) - > ULN 
Protein/creatinine ratio mg/mmol > ULN 

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 July 2017 
  
 
Confidential Page 30 of 43 Albumin/creatinine ratio mg/mmol > ULN 
ALT = alanine aminotransferase, AST = aspartate aminotransferas e, BUN = blood urea nitrogen, GFR = glomerular 
filtration rate, PCS = potentially clinically significant, ULN = upper limit of normal. 
Urinalysis parameters that are not fully numeric (ie, blood, bi lirubin, glucose, ketones, leukocyte 
esterase, protein [dipstick results], and nitrite) will be incl uded in a listing.  
Over the course of the study, there may be lab tests performed that were not specified in the 
protocol. These tests will not be  summarized but will be includ ed in the listings and flagged as 
non-protocol tests. 
12.3 ECGs 
ECGs will be performed in triplicate at the Screening Visit, Da y 1, Week 2, Week 4, Week 8, 
Week 12, and the ET Visit, if appli cable. The following ECG par ameters will be reported by [CONTACT_562412]: heart rate, PR interval, QRS duration, QT inter val (uncorrected), QT interval 
corrected for heart rate using Bazettâ€™s formula  (QTcB) and using Fridericiaâ€™s formula (QTcF), 
and T-wave amplitude. The avera ge of the 3 values for a given E CG parameter (eg, heart rate) 
will be used for analysis. In cases where an ECG is performed i n duplicate, the average will be 
used, and in cases where only one ECG is performed, the result of the single ECG will be used. CFBL and percent CFBL will be ca lculated for each parameter at each time point (including end 
of treatment) and summari zed by [CONTACT_1570].  
Further, QTcB and QTcF will also be investigated through PCS ta bles (see Table 4 below for the 
criteria). The number and percent of subjects meeting the crite ria below will be summarized by 
[CONTACT_1570]. Summaries will be given for both overall (ie, any time post-baseline) and by 
[CONTACT_765]. Subjects will be include d in all categories for which th ey qualify. For criteria on the 
â€œActualâ€ values, the denominator for the percentages is the number of subjects who had a post-baseline assessment for e ach parameter. For criteria on th e change, the denominator is the 
number of subjects who had a base line and post-baseline assessment. 
Table 4. ECG PCS Criteria 
ECG Parameter Actual or Change PCS Criteria 
QTcB (msec) Actual > 450 
Actual > 480 
Actual > 500 
CFBL (increase) > 30 
CFBL (increase) > 60 
QTcF  (msec) Actual > 450 
Actual > 480 
Actual > 500 
CFBL (increase) > 30 
CFBL (increase) > 60 
CFBL = change from baseline, ECG = electrocardiogram, PCS = pot entially clinically significant, QTcB = QT 
interval corrected for heart rate with Bazettâ€™s formula , QTcF = QT interval corrected for heart rate with Fridericiaâ€™s 
formula. 
All interpretations along with the corresponding details will b e provided in a listing. 

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 July 2017 
  
 
Confidential Page 31 of 43 12.4 Vital Signs and Weight 
Vital signs comprise pulse rate, diastolic blood pressure (DBP), SBP, respi[INVESTIGATOR_1487], and 
temperature. Except for the Follow-up Visit, vital signs and we ight will be measured at all study 
visits. CFBL and percent CFBL w ill be calculated  for each vital sign and weight parameter at 
each time point (including end of t reatment) and summarized by [CONTACT_1570]. Additionally, 
for DBP and SBP, the previous table will be presented by [CONTACT_562413] 
(yes or no) and treatment group. 
Vital signs and weight will also be presented in a listing. 
12.[ADDRESS_739128]â€™s first study visit (either at the  
Pre-Screening Visit or the Screening Visit) and last study visi t (either at the Week 12 Visit or the 
ET Visit). At all other Study Visits (eg, Week 2) where a full physical examination was not 
conducted except the Follow-up Visit, a symptom-directed physic al examination will be 
performed. Additionally, a symptom-directed physical examinatio n will only be conducted at the 
Follow-up Visit for subjects who ha d an abnormal result at Week  12 (or the ET visit) or had an 
ongoing treatment-related AE. For each assessment (general appearance, respi[INVESTIGATOR_696], etc.), th e number and percentage of normal 
and abnormal findings will be provided by [CONTACT_562414] p and visit for the SAS. The 
denominator used to calculate the percentage will be the number  of subjects that underwent a 
physical examination at the corresponding visit. 

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 July 2017 
  
 
Confidential Page 32 of 43 13 OTHER RELEVANT DATA ANALYSES/SUMMARIES 
13.1 Medical History  
Medical history will be coded using MedDRA version 19.1. Medica l history will be summarized 
by [CONTACT_562415]. At 
each level of summarization, subjects who report one or more medical history events within a 
given level (SOC/PT) will only be counted once at that level. The table will be sorted by [CONTACT_2946] (alphabetically) and then by [CONTACT_6214] (decreasing frequency in the ge mcabene column within each 
SOC). 
13.2 Prior and Concomitant Medications 
Prior and concomitant medications will be coded using the World Health Organization (WHO) Drug Dictionary version [ADDRESS_739129]â€™s first dose  (ie, medication stop date < date of first dose). A 
concomitant medication is define d as a medication with a start date on or before the date of the 
subjectâ€™s last dose  (ie, medication start date â‰¤ date of last dose) and a stop date  on or after the 
date of the subjectâ€™s first dose  (ie, medication stop date â‰¥ date of first dose) ; thus, a medication 
that is ongoing at the time of the subjectâ€™s first dose is considered conco mitant. Partial and 
missing dates will be imputed using rules in Appendix 2 .  
Prior and concomitant medications will be summarized in separat e tables and listings. 
Medications will be summarized by [CONTACT_103256] 3 (level 3 indicate s the therapeutic/pharmacologic 
subgroup) alphabetically and preferred name (decreasing frequen cy in the Gemcabene column 
within each ATC) by [CONTACT_562406]. At each  level of summarization, 
subjects who report one or more medications within a given leve l (eg, ATC and preferred name) 
will only be counted once at that level. Excluded medications will be flagged in the concomitant medications listing.  
13.[ADDRESS_739130]â€™s last dose (ie, procedure start date â‰¤ date of last dose) and a stop da te on or after the date of the 
subjectâ€™s first dose (ie, procedure stop date â‰¥ date of first dose).  Concomitant procedures will be 
presented in a listing containing verbatim terms for the SAS. 
 

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 July 2017 
  
 
Confidential Page 33 of 43 14 REFERENCES 
1. Dâ€™Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General 
cardiovascular risk profile for use in primary care the Framing ham Heart Study. Circulation. 
2008 Feb 12;117(6):743-53. 
2. Wilson PW, Dâ€™Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction 
of coronary heart disease using risk factor categories. Circula tion. 
1998 May 1;97(18):1837-47. 
3. Stein E, Bays H, Koren M, Bakker-Arkema R, Bisgaier C. Efficacy  and safety of gemcabene 
as add-on to stable statin therapy in hypercholesterolemic pati ents. Journal of Clinical 
Lipi[INVESTIGATOR_37444]. [ADDRESS_739131] 31;10(5):1212-22. 
4. Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM,  Daumit GL, Hsiao J, 
Swartz MS, Stroup TS, Lieberman JA. Impact of antipsychotic tre atment on nonfasting 
triglycerides in the CATIE Schizophrenia Trial phase 1. Schizop hrenia research. 2008 Aug 
31;103(1):104-9. 
5. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safe ty of colesevelam in 
patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-
based therapy. Archives of I nternal Medicine. 2008 Jul 28;168(1 4):1531-40. 
6. Conover WJ, Iman RL. Analysis of covariance using the rank tran sformation. Biometrics. 
1982 Sep 1:715-24. 

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 Jul 2017 
  
 
Confidential Page 34 of 43 15 APPENDICES 
Appendix 1. Schedule of Assessments and Procedures 
 Pre-
Screening
a Screening
b Treatment Periodc Follow-
upd 
ET up to 
Day-14 Day 1e Week 2 
(Day 15 Â± 3 
days) Week 4 (Day 
29 Â± 3 days) Week 8 
(Day 57 Â± 3 
days) Week 12 (Day 
85, or up to 3 
days earlier) Day 113 Â± 
3 days 
Visit S1 Visit T1 Visit T2 Visit T3 Visit T4 Visit T5  
Informed consent  X Xf        
Inclusion/exclusion criteria  X X        
Medical/surgical history and 
demographics  X Xf        
Full physical examinationg X Xf     X  X 
Symptom-directed physical 
examination   Xh X X X X  Xi  
Vital signsj, heightk, and weight  X X X X X X X  X 
Body Mass Index (BMI)  X X        
Urinalysisl X X X  X X X Xi X 
Serum/urine pregnancy testm X X X X X X X  X 
Safety chemistry panel, 
coagulation, and  hematologyn X X X X X X X Xi X 
TSH, HbA1c, and serologyo X Xf     X  X 
Fasting lipid panelp; LDL-C 
ultracentrifugation when 
necessary  Xq X X X X X X  X 
Fasting apolipoproteinsr   X  X X X  X 
PCSK9    X    X  X 
hsCRP, SAA, fibrinogen, and 
adiponectin    X    X  X 
Fasting plasma glucose, insulin    X    X  X 
Randomization    X       
Study drug administrations   X X X X X   
Dispense study drug and 
instructions    X X X X    

*HPFDEHQH *HPSKLUH7KHUDSHXWLFV,QF
6WDWLVWLFDO$QDO\VLV3ODQ*(0 -XO
 

&RQILGHQWLDO 3DJHRI Pre-
Screening
a Screening
b Treatment Periodc Follow-
upd 
ET up to 
Day-14 Day 1e Week 2 
(Day 15 Â± 3 
days) Week 4 (Day 
29 Â± 3 days) Week 8 
(Day 57 Â± 3 
days) Week 12 (Day 
85, or up to 3 
days earlier) Day 113 Â± 
3 days 
Visit S1 Visit T1 Visit T2 Visit T3 Visit T4 Visit T5  
&RPSOLDQFHFKHFN     ; ; ; ;  ;
'LHWDU\LQVWUXFWLRQVW ; ; ; ; ; ;   
OHDG(&*X  ; ; ; ; ; ;  ;
,QLWLDWHZDVKRXW  ;        
$GYHUVHHYHQWV  ;Y ;Y ; ; ; ; ; ; ;
&RQFRPLWDQWPHGLFDWLRQV  ; ;I ; ; ; ; ; ; ;
5HVHUYHVDPSOHV    ; ; ; ; ;  ;
$SR DSROLSRSURWHLQ%0, ERG\PDVVLQGH[(&* HOHFWURFDUGL RJUDPH&5) HOHFWURQLFFDVHUH SRUWIRUP(7 (DUO\7HUPLQDWL RQ+%9 KHSDWLWLV%YLUXV+E$F 
KHPRJORELQ$F+&9 KHSDWLWLV&YLUXV+'/ & KLJKGHQVLW\OLSRSURWHLQFKROHVWHURO+,9 KXPDQLPPXQRGH ILFLHQF\YLUXV+R)+ KRPR]\JRXVIDPLOLDO
K\SHUFKROHVWHUROHPLDKV&53 KLJKVHQVLWLYLW\& UHDFWLYHSURWHLQ/'/& ORZGHQVLW\OLSRSURWHLQFKROHVWHURO /SD OLSRSURWHLQD1&(3$73 ,,, 1DWLRQDO&KROHVWHURO
(GXFDWLRQ3URJUDP$GXOW7UHDWPHQW3DQHO,,,1*$/ QHXWURSKLO JHODWLQDVHDVVRFLDWHGOLSRFDOLQQRQ+'/& QRQKLJKGHQVLW\OLSRSURWHLQ FKROHVWHURO 
6$$ VHUXPDP\ORLG$7& WRWDOFKROHVWHURO7* WULJO\FHUL GH76+ WK\URLGVWLPXODWLQJKRUPRQH9/'/& YHU\ORZGHQVLW \
OLSRSURWHLQFKROHVWHURO 
D2QO\VXEMHFWVUHTXLULQJDZDVKRXWSHULRGZLOOSDUWLFLSDWHLQW KH3UH6FUHHQLQJ9LVLW6SHFLILFDOO\ LQKLELWRUVZLOOUHTXLUHDQZHHNZDVKRXWSHULRGILEUDWHVZLOO
UHTXLUHDZHHNZDVKRXWSHULRGDQGQLDFLQVRURWKHUOLSLGUH JXODWLQJWKHUDSLHVVXFKDVELOHDFLGVHTXHVWUDQWVZLOOUHTXLUH DZHHNZDVKRXWSH ULRGSULRUWRWKH6FUHHQLQJ
9LVLW
E$OOHOLJLEOHVXEMHFWVZLOOSDUWLFLSDWHLQWKH6FUHHQLQJ9LVLWX SWRGD\VSULRUWR'D\)RUVXEMHFWVWDNLQJWKHUHTXLUHG VWDEOHVWDWLQWKHUDS\IRU!ZHHNVDWWKH6FUHHQLQJ
9LVLWDQGGRQRWUHTXLUHDZDVKRXWSHULRGWKH6FUHHQLQJ9LVLW ZLOOEHWKHLUILUVWVWXG\YLVLW
F6WXG\DVVHVVPHQWVZLOOEHFRPSOHWHGÂ“GD\VRIJLYHQWLPHSRLQ WIRUDOOVWXG\YLVLWVIURP'D\WKURXJK:HHN:HHNDVVH VVPHQWVFDQEHSHUIRUPHGXSWRGD\VSULRU
WR:HHNEXWQRWDIWHU:HHN
G7KH)ROORZXS9LVLWZLOOEHFRQGXFWHGDVDWHOHSKRQHFDOOZHH NVÂ“GD\VDIWHUWKHODVWGRVHRIVWXG\GUXJXQOHVVWKHVXE MHFWUHTXLUHVDVLWHYLVLWGXHWRDQDEQRUPDOUHVXOW
DW:HHNRUWKH(79LVLWLI DSSOLFDEOHRUDQRQJRLQJWUHDW PHQWUHODWHGDGYHUVHHYHQW
H3URFHGXUHVZLOOEHSHUIRUPHGSUH GRVH7KH,QYHVWLJDWRUZLOOLQTXLUHZLWKWKHVXEMHFWDW'D\W RGHWHUPLQHLIWKHUHKDYHEHHQDQ\FKDQJHVLQWKHVXEMHFWÂ¶VKH DOWKDIIHFWLQJ
HOLJLELOLW\RUUHTXLULQJDQXSGDWHWRWKHLUPHGLFDODQGVXUJLFD OKLVWRU\
I)RUVXEMHFWVZKRUHTXLUHGDZDVKRXWSHULRGDQGFRPSOHWHGWKH3 UH6FUHHQLQJ9LVLWWKHIROORZLQJ6FUHHQLQJ9LVLWSURFHGXUHVZL OOQRWEHUHSHDWHGLQIRUPHGFRQVHQWIXOO
SK\VLFDOH[DPLQDWLRQKHLJKW76++E$FDQGVHURORJ\+%9+& 9DQG+,9VFU HHQLQJ8SGDWHVDVQHHGHGZLOOEHPDGHWRPHGLFDOVXUJLFDOKL VWRU\GHPRJUDSKLFVDQG
FRQFRPLWDQWPHGLFDWLRQV
J$IXOOSK\VLFDOH[DPLQDWLRQLQFOXGHVJHQLWRXULQDU\H[DPLQDWLRQ SHUWKH,QYHVWLJDWRUÂ¶VGLVFUHWLRQDQGGRHVQRWLQFOXGHDUHFWD OH[DPLQDWLRQ
K2QO\IRUVXEMHFWVZKRUHTXLUHGDZDVKRXWSHULRGDQGFRPSOHWHG WKHIXOOSK\VLFDOH[DPLQDWLRQ DWWKH3UH6FUHHQLQJ9LVLW
L2QO\IRUVXEMHFWVZKRKDGDQDEQR UPDOUHVXOWDW:HHNRUWKH (79LVLWLIDSSOLFDEOHRUDQRQJRLQJWUHDWPHQWUHODWHGDGYHU VHHYHQW
M9LWDOVLJQVLQFOXGHSXOVHUDWHEORRGSUHVVXUHUHVSLUDWLRQUDW HDQGWHPSHUDWXUH%ORRGSUHVVXUHVKRXOGEHREWDLQHGLQWKHVH DWHGSRVLWLRQDIWHUWKHVXEMHFWKDVUHVWHG
FRPI[INVESTIGATOR_100225]\IRUDWOHDVWPLQXWHV%ORRGSUHVVXUHDWWKH6FUHH QLQJ9LVLWVKRXOGEHREWDLQHGL QERWKDUPVDQGWKHDUPZLWKWKH KLJKHVWYDOXHVKRXOGEHXVHGIRURQJRLQJCI
CI
CI
Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 Jul 2017 
  
 
Confidential Page 36 of 43  Pre-
Screening
a Screening
b Treatment Periodc Follow-
upd 
ET up to 
Day-14 Day 1e Week 2 
(Day 15 Â± 3 
days) Week 4 (Day 
29 Â± 3 days) Week 8 
(Day 57 Â± 3 
days) Week 12 (Day 
85, or up to 3 
days earlier) Day 113 Â± 
[ADDRESS_739132] throughout the study when possible. 
Care should be taken to ensure a n appropriate cuff size is util ized. 
k Height will be measured only at the subjec tâ€™s first study visit, either at the Pre -Screening Visit or the Screening Visit. 
l A urine microscopic examination will be performed when the dipstick result is abnormal (positive for blood, leukocyte esterase , or nitrites). Urine protein:creatinine ratio 
(albumin:creatinine) will be performed at the Screening Visit, Day 1, Week 4, Week 12, the Follow-up Visit (only for subjects who had an abnormal resu lt at Week 12 [or the 
ET Visit, if applicable] or an ongoing treatment-related advers e event), and the ET Visit, if applicable. Urinary NGAL will be  measured at Day 1, Week 4, Week 12, the 
Follow-up Visit (only for subjects who had an abnormal result a t Week 12 [or the ET Visit, if applicable] or an ongoing treatm ent-related adverse event), and the ET Visit, if 
applicable. 
m For women of child-bearing potential only, a serum pregnancy te st will be conducted at the Screening Visit, Week 12, and the E T Visit, i f applicable. A urine pregnancy test 
will be conducted at the Pre-Screening Visit, Day 1, Week 2, We ek 4, and Week 8.  
n Clinically significant abnormal creatinine results at Week 12 (or the ET Visit, if applicable) will also be followed-up 2 week s (Â± 3 days ) after the last dose of study drug in 
addition to the Week 4 (Â± 3 days) Follow-up Visit. See Appendix B in the protocol for a list of analytes and description of wh en repeat or reflexive testing will be r equired.  
o Thyroid-stimulating hormone, HbA1c, and s erology (HBV, HCV, and HIV) will be measured at the subjectâ€™s first study visit, either at the Pre -Screening Visit, if applicable, 
or the Screening Visit. Only HbA1c will be measured at Week 12,  and the ET Visit, if applicable.  
p Includes LDL-C, non-HDL-C, TC, TG, HDL-C, and VLDL- C. Fasting will be defined as no food or caloric beverage for a t least [ADDRESS_739133] water. 
r Includes ApoB, ApoA-I, ApoA-II, ApoA-V, ApoC-II, ApoC-III, ApoE , and Lp(a). Fasting will be defined as no food or caloric beve rage for at least [ADDRESS_739134] water.  
s Study drug will be administered at the site on Day 1. Subjects will self-dose at all other times during the Treatment Period.  
t Subjects will be counseled on a low-fat, low-cholesterol diet ( NCEP ATP-III guidelines or equivalent). 
u Subjects should be lying quietly in a fully supi[INVESTIGATOR_562398] [ADDRESS_739135] udy drug (Day 1) should be reported as an update to medical his tory as well as be reported on the appropriate 
adverse event eCRF. 

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 Jul 2017 
  
 
Confidential Page 37 of 43 
 Appendix 2. Prior and Concomitant Medications and Smoking Statu s 
Date Imputation 
Imputation Rules for Pa rtial Dates (D = day, M = month, Y = year) 
Parameter Missing Additional Conditions Imputation 
Start date  D only M and Y same as M and Y of first dose 
of study drug Date of first dose of study drug 
M and/or Y not same as date of first 
dose of study drug First day of month 
M and D Y same as Y of first dose of study drug Date of first dose of study drug 
Y not same as Y of first dose of study 
drug Use Jan [ADDRESS_739136] dose of study drug 
M and/or Y not same as date of last 
dose of study drug Last day of month 
M and D Y same as Y of last dose of study drug Date of last dose of study drug 
Y not same as Y of last dose of study 
drug Use Dec [ADDRESS_739137] dose of study drug 
Note: In all cases, if an estimated start date is after a compl ete stop date, use the fir st day of the stop date 
month.  
Similarly, if the estimated stop date  is before a complete or imputed start date, use the last day of  the start day 
month. 
 

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 Jul 2017 
  
 
Confidential Page 38 of 43 
 Appendix 3. ATC Categories and Descriptions of Hypertensive 
Treatments 
The WHO Drug Dictionary version 01 Mar 2016 was used to identif y the following ATC 
categories and descriptions which will be used to identify hype rtensive treatment.  
ATC2/ATC2 Description1 ATC3/ATC3 Description ATC4/ATC4 Description 
C02/ANTIHYPERTENSIVES C02A/ ANTIADRENERGIC AGENTS, 
CENTRALLY ACTING C02AA/ Rauwolfia alkaloids 
C02/ANTIHYPERTENSIVES C02A/ ANTIADRENERGIC AGENTS, 
CENTRALLY ACTING C02AB/Methyldopa 
C02/ANTIHYPERTENSIVES C02A/ ANTIADRENERGIC AGENTS, 
CENTRALLY ACTING C02AC/Imidazoline receptor 
agonists 
C02/ANTIHYPERTENSIVES C02B/ANTIADRENERGIC AGENTS, 
GANGLION-BLOCKING C02BA/Sulfonium derivatives 
C02/ANTIHYPERTENSIVES C02B/ANTIADRENERGIC AGENTS, 
GANGLION-BLOCKING C02BB/Secondary and tertiary 
amines 
C02/ANTIHYPERTENSIVES C02B/ANTIADRENERGIC AGENTS, 
GANGLION-BLOCKING C02BC/Bisquaternary ammonium 
compounds 
C02/ANTIHYPERTENSIVES C02C/ANTIADRENERGIC AGENTS, 
PERIPHERALLY ACTING C02CA/Alpha-adrenoreceptor 
antagonists 
C02/ANTIHYPERTENSIVES C02C/ANTIADRENERGIC AGENTS, 
PERIPHERALLY ACTING C02CC/Guanidine derivatives 
C02/ANTIHYPERTENSIVES C02D/ARTERIOLAR SMOOTH 
MUSCLE, AGENTS ACTING ON C02DA/Thiazide derivatives 
C02/ANTIHYPERTENSIVES C02D/ARTERIOLAR SMOOTH 
MUSCLE, AGENTS ACTING ON C02DB/Hydrazinophthalazine 
derivatives 
C02/ANTIHYPERTENSIVES C02D/ARTERIOLAR SMOOTH 
MUSCLE, AGENTS ACTING ON C02DC/Pyrimidine derivatives 
C02/ANTIHYPERTENSIVES C02D/ARTERIOLAR SMOOTH 
MUSCLE, AGENTS ACTING ON C02DD/Nitroferricyanide 
derivatives 
C02/ANTIHYPERTENSIVES C02D/ARTERIOLAR SMOOTH 
MUSCLE, AGENTS ACTING ON C02DG/Guanidine derivatives 
C02/ANTIHYPERTENSIVES C02K/OTHER ANTIHYPERTENSIVES C02KA/Alkaloids, excl. 
rauwolfia 
C02/ANTIHYPERTENSIVES C02K/OTHER ANTIHYPERTENSIVES C02KB/Tyrosine hydroxylase 
inhibitors 
C02/ANTIHYPERTENSIVES C02K/OTHER ANTIHYPERTENSIVES C02KC/MAO inhibitors 
C02/ANTIHYPERTENSIVES C02K/OTHER ANTIHYPERTENSIVES C02KD/Serotonin antagonists 
C02/ANTIHYPERTENSIVES C02K/OTHER ANTIHYPERTENSIVES C02KW/Herbal 
antihypertensives, other 
C02/ANTIHYPERTENSIVES C02K/OTHER ANTIHYPERTENSIVES C02KX/Antihypertensives for 
pulmonary arterial hypertension 
C02/ANTIHYPERTENSIVES C02L/ANTIHYPERTENSIVES AND 
DIURETICS IN COMBINATION C02LA/Rauwolfia alkaloids and 
diuretics in combination 
C02/ANTIHYPERTENSIVES C02L/ANTIHYPERTENSIVES AND 
DIURETICS IN COMBINATION C02LB/Methyldopa and diuretics 
in combination 
C02/ANTIHYPERTENSIVES C02L/ANTIHYPERTENSIVES AND 
DIURETICS IN COMBINATION  C02LC/Imidazoline receptor 
agonists in combination with 
diuretics 

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 Jul 2017 
  
 
Confidential Page 39 of 43 C02/ANTIHYPERTENSIVES C02L/ANTIHYPERTENSIVES AND 
DIURETICS IN COMBINATION C02LE/Alpha-adrenoreceptor 
antagonists and diuretics 
C02/ANTIHYPERTENSIVES C02L/ANTIHYPERTENSIVES AND 
DIURETICS IN COMBINATION C02LF/Guanidine derivatives and 
diuretics 
C02/ANTIHYPERTENSIVES C02L/ANTIHYPERTENSIVES AND 
DIURETICS IN COMBINATION C02LG/Hydrazinophthalazine 
derivatives and diuretics 
C02/ANTIHYPERTENSIVES C02L/ANTIHYPERTENSIVES AND 
DIURETICS IN COMBINATION  C02LK/Alkaloids, excl. 
rauwolfia, in combination with 
diuretics 
C02/ANTIHYPERTENSIVES C02L/ANTIHYPERTENSIVES AND 
DIURETICS IN COMBINATION C02LL/MAO inhibitors and 
diuretics 
C02/ANTIHYPERTENSIVES C02L/ANTIHYPERTENSIVES AND 
DIURETICS IN COMBINATION C02LN/Serotonin antagonists and 
diuretics 
C02/ANTIHYPERTENSIVES C02L/ANTIHYPERTENSIVES AND 
DIURETICS IN COMBINATION C02LX/Other antihypertensives 
and diuretics 
C02/ANTIHYPERTENSIVES C02N/COMBINATIONS OF 
ANTIHYPERTENSIVES IN ATC -GR. 
C02 - 
C03/DIURETICS C03A/LOW-CEILING DIURETICS, 
THIAZIDES C03AA/Thiazides, plain 
C03/DIURETICS C03A/LOW-CEILING DIURETICS, 
THIAZIDES C03AB/Thiazides and potassium 
in combination 
C03/DIURETICS C03A/LOW-CEILING DIURETICS, 
THIAZIDES  C03AH/Thiazides, combinations 
with psycholeptics and/or 
analgesics 
C03/DIURETICS C03A/LOW-CEILING DIURETICS, 
THIAZIDES C03AX/Thiazides, combinations 
with other drugs 
C03/DIURETICS C03B/LOW-CEILING DIURETICS, 
EXCL. THIAZIDES C03BA/Sulfonamides, plain 
C03/DIURETICS C03B/LOW-CEILING DIURETICS, 
EXCL. THIAZIDES C03BB/Sulfonamides and 
potassium in combination 
C03/DIURETICS C03B/LOW-CEILING DIURETICS, 
EXCL. THIAZIDES C03BC/Mercurial diuretics 
C03/DIURETICS C03B/LOW-CEILING DIURETICS, 
EXCL. THIAZIDES C03BD/Xanthine derivatives 
C03/DIURETICS C03B/LOW-CEILING DIURETICS, 
EXCL. THIAZIDES C03BK/Sulfonamides, 
combinations with other drugs 
C03/DIURETICS C03B/LOW-CEILING DIURETICS, 
EXCL. THIAZIDES C03BX/Other low-ceiling 
diuretics 
C03/DIURETICS C03C/HIGH-CEILING DIURETICS C03CA/Sulfonamides, plain 
C03/DIURETICS C03C/HIGH-CEILING DIURETICS C03CB/Sulfonamides and 
potassium in combination 
C03/DIURETICS C03C/HIGH-CEILING DIURETICS C03CC/Aryloxyacetic acid 
derivatives 
C03/DIURETICS C03C/HIGH-CEILING DIURETICS C03CD/Pyrazolone derivatives 
C03/DIURETICS C03C/HIGH-CEILING DIURETICS C03CX/Other high-ceiling 
diuretics 
C03/DIURETICS C03D/POTASSIUM-SPARING 
AGENTS C03DA/Aldosterone antagonists 
C03/DIURETICS C03D/POTASSIUM-SPARING 
AGENTS C03DB/Other potassium-sparing 
agents 

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 Jul 2017 
  
 
Confidential Page 40 of 43 C03/DIURETICS C03E/DIURETICS AND POTASSIUM-
SPARING AGENTS IN 
COMBINATION C03EA/Low-ceiling diuretics and 
potassium -sparing agents 
C03/DIURETICS C03E/DIURETICS AND POTASSIUM-
SPARING AGENTS IN 
COMBINATION C03EB/High-ceiling diuretics and 
potassium -sparing agents 
C03/DIURETICS C03X/OTHER DIURETICS C03XA/Vasopressin antagonists 
C03/DIURETICS C03X/OTHER DIURETICS C03XW/Herbal diuretics, other 
C07/BETA BLOCKING 
AGENTS C07A/BETA BLOCKING AGENTS C07AA/Beta blocking agents, 
non-selective 
C07/BETA BLOCKING 
AGENTS C07A/BETA BLOCKING AGENTS C07AB/Beta blocking agents, 
selective 
C07/BETA BLOCKING 
AGENTS C07A/BETA BLOCKING AGENTS C07AG/Alpha and beta blocking 
agents 
C07/BETA BLOCKING 
AGENTS C07B/BETA BLOCKING AGENTS 
AND THIAZIDES C07BA/Beta blocking agents, 
non-selective, and thiazides 
C07/BETA BLOCKING 
AGENTS C07B/BETA BLOCKING AGENTS 
AND THIAZIDES C07BB/Beta blocking agents, 
selective, and thiazides 
C07/BETA BLOCKING 
AGENTS C07B/BETA BLOCKING AGENTS 
AND THIAZIDES C07BG/Alpha and beta blocking 
agents and thiazides 
C07/BETA BLOCKING 
AGENTS C07C/BETA BLOCKING AGENTS 
AND OTHER DIURETICS C07CA/Beta blocking agents, 
non-selective, and other diuretics 
C07/BETA BLOCKING 
AGENTS C07C/BETA BLOCKING AGENTS 
AND OTHER DIURETICS C07CB/Beta blocking agents, 
selective, and other diuretics 
C07/BETA BLOCKING 
AGENTS C07C/BETA BLOCKING AGENTS 
AND OTHER DIURETICS C07CG/Alpha and beta blocking 
agents and other diuretics 
C07/BETA BLOCKING 
AGENTS  C07D/BETA BLOCKING AGENTS, 
THIAZIDES AND OTHER 
DIURETICS C07DA/Beta blocking agents, 
non-selective, thiazides and other 
diuretics 
C07/BETA BLOCKING 
AGENTS  C07D/BETA BLOCKING AGENTS, 
THIAZIDES AND OTHER 
DIURETICS C07DB/Beta blocking agents, 
selective, thiazides and other 
diuretics 
C07/BETA BLOCKING 
AGENTS C07E/BETA BLOCKING AGENTS 
AND VASODILATORS C07EA/Beta blocking agents, 
non-selective, and vasodilators 
C07/BETA BLOCKING 
AGENTS C07E/BETA BLOCKING AGENTS 
AND VASODILATORS C07EB/Beta blocking agents, 
selective, and vasodilators 
C07/BETA BLOCKING 
AGENTS  C07F/BETA BLOCKING AGENTS 
AND OTHER ANTIHYPERTENSIVES C07FA/Beta blocking agents, 
non-selective, and other 
antihypertensives 
C07/BETA BLOCKING 
AGENTS  C07F/BETA BLOCKING AGENTS 
AND OTHER ANTIHYPERTENSIVES C07FB/Beta blocking agents, 
selective, and other 
antihypertensives 
C08/CALCIUM CHANNEL 
BLOCKERS  C08C/SELECTIVE CALCIUM 
CHANNEL BLOCKERS WITH 
MAINLY VASCULAR EFFECTS C08CA/Dihydropyridine 
derivatives  
C08/CALCIUM CHANNEL 
BLOCKERS  C08C/SELECTIVE CALCIUM 
CHANNEL BLOCKERS WITH 
MAINLY VASCULAR EFFECTS C08CX/Other selective calcium 
channel blockers with mainly 
vascular effects 
C08/CALCIUM CHANNEL 
BLOCKERS  C08D/SELECTIVE CALCIUM 
CHANNEL BLOCKERS WITH 
DIRECT CARDIAC EFFECTS C08DA/Phenylalkylamine 
derivatives  

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 Jul 2017 
  
 
Confidential Page 41 of 43 C08/CALCIUM CHANNEL 
BLOCKERS  C08D/SELECTIVE CALCIUM 
CHANNEL BLOCKERS WITH 
DIRECT CARDIAC EFFECTS C08DB/Benzothiazepi[INVESTIGATOR_562399]  
C08/CALCIUM CHANNEL 
BLOCKERS C08E/NON-SELECTIVE CALCIUM 
CHANNEL BLOCKERS C08EA/Phenylalkylamine 
derivatives 
C08/CALCIUM CHANNEL 
BLOCKERS C08E/NON-SELECTIVE CALCIUM 
CHANNEL BLOCKERS C08EX/Other non-selective 
calcium channel blockers 
C08/CALCIUM CHANNEL 
BLOCKERS C08G/CALCIUM CHANNEL 
BLOCKERS AND DIURETICS C08GA/Calcium channel 
blockers and diuretics 
C09/AGENTS ACTING ON 
THE RENIN -ANGIOTENSIN 
SYSTEM C09A/ACE INHIBITORS, PLAIN C09AA/ACE inhibitors, plain 
C09/AGENTS ACTING ON 
THE RENIN -ANGIOTENSIN 
SYSTEM C09B/ACE INHIBITORS, 
COMBINATIONS  C09BA/ACE inhibitors and 
diuretics  
C09/AGENTS ACTING ON 
THE RENIN -ANGIOTENSIN 
SYSTEM C09B/ACE INHIBITORS, 
COMBINATIONS  C09BB/ACE inhibitors and 
calcium channel blockers  
C09/AGENTS ACTING ON 
THE RENIN -ANGIOTENSIN 
SYSTEM C09B/ACE INHIBITORS, 
COMBINATIONS  C09BX/ACE inhibitors, other 
combinations  
C09/AGENTS ACTING ON 
THE RENIN -ANGIOTENSIN 
SYSTEM C09C/ANGIOTENSIN II 
ANTAGONISTS, PLAIN  C09CA/Angiotensin II 
antagonists, plain  
C09/AGENTS ACTING ON 
THE RENIN -ANGIOTENSIN 
SYSTEM C09D/ANGIOTENSIN II 
ANTAGONISTS, COMBINATIONS C09DA/Angiotensin II 
antagonists and diuretics 
C09/AGENTS ACTING ON 
THE RENIN -ANGIOTENSIN 
SYSTEM C09D/ANGIOTENSIN II 
ANTAGONISTS, COMBINATIONS C09DB/Angiotensin II 
antagonists and calcium channel 
blockers 
C09/AGENTS ACTING ON 
THE RENIN -ANGIOTENSIN 
SYSTEM C09D/ANGIOTENSIN II 
ANTAGONISTS,  COMBINATIONS  C09DX/Angiotensin II 
antagonists, other combinations 
C09/AGENTS ACTING ON 
THE RENIN -ANGIOTENSIN 
SYSTEM C09X/OTHER AGENTS ACTING ON 
THE RENIN -ANGIOTENSIN SYSTEM C09XA/Renin-inhibitors 
ATC = anatomical therapeutic chemical, MAO = monoamine oxidase, ACE = angiotensin-converting enzyme 
[ADDRESS_739138] ATC1/ATC1 Description=C/CARDIOVASCU LAR SYSTEM. 
 
  

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-301 10 Jul 2017 
  
 
Confidential Page 42 of 43 Appendix 4. Sex-specific Framingham Risk Score algorithms 
Framingham Risk Score (10-year CVD risk) for each subject is ba sed on sex-specific Cox 
proportional hazard models. [ADDRESS_739139] is:  
ÝŒÆ¸àµŒÍ³àµ†Üµ à¬´áˆºÝáˆ»à­£à­¶à­®áˆºÏƒà°‰à³”à¯‘à³”à¬¿Ïƒà°‰à³”à¯‘à´¤à³”à³›
à³”à°¸à°­áˆ»à³›à³”à°¸à°­, 
 
where Üµà¬´áˆºÝáˆ» is baseline survival at follow-up time Ý( 10 years), ßšà¯œ is the estimated regression 
coefficient (log hazard ratio), Üºà¯œ is the log-transformed value of the i -th risk factor if 
continuous, Üºà´¤à¯œ is the corresponding mean, and ÝŒ denotes the number of risk factors. For 
women, baseline 10-year surviva l is 0.[ZIP_CODE]. For men, the basel ine 10-year survival is 
0.[ZIP_CODE].  
   

Gemcabene Gemphire Therapeutics Inc. 
Statistical Analysis Plan: GEM-[ADDRESS_739140] ratum will not be included in the 
model (where appropriate).  
â€¢ In addition to percent CFBL to Week 12 in LDL-C, all other seco ndary efficacy analyses 
will be conducted within each baseline statin-intensity stratum .  
 
